Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.4    
    

EXECUTION
COPY 

 
 

PURCHASE AND SALE AGREEMENT    
    

BY AND BETWEEN  

 DANIEL J. BATES

JOHN J. KOLENG JR.

FENG ZHANG

MICHAEL M. CROWLEY

JAMES W. MCGINITY

AND ROBERT O. WILLIAMS, III  

 AS SELLERS,  

 AND  

 LAB INTERNATIONAL INC.  

 AS PURCHASER  

 January 10, 2007  

   TABLE OF CONTENTS  

	I.	 	Purchase and Transfer of the Membership Interests	 	1
	

 	
 	

A.	
 	

Purchase and Transfer of the Membership Interests	
 	

1
	 	 	B.	 	Purchase Price	 	1
	 	 	C.	 	Payment of Purchase Price at Closing	 	1
	 	 	D	 	Share Issuances and Payments Contingent upon Meeting Milestones	 	2
	 	 	E.	 	Additional Purchase Price Covenants	 	3
	 	 	F.	 	Manner of Payments	 	4
	 	 	G.	 	Transfer of Title	 	4
	

II.	
 	

Closing	
 	

5
	

 	
 	

A.	
 	

Closing	
 	

5
	 	 	B.	 	Conditions Precedent to the Obligations of Purchaser	 	5
	 	 	C.	 	Conditions Precedent to the Obligations of Sellers	 	6
	 	 	D.	 	Closing Actions	 	6
	

III.	
 	

Representations and Warranties	
 	

7
	

 	
 	

A.	
 	

Sellers' Representations and Warranties	
 	

7
	 	 	B.	 	Representations and Warranties of the Purchaser	 	17
	

IV.	
 	

Covenants	
 	

18
	

 	
 	

A.	
 	

Appointment	
 	

18
	 	 	B.	 	Waiver of First Refusal Rights	 	18
	 	 	C.	 	Publicity	 	18
	 	 	D.	 	Diligence	 	18
	 	 	E.	 	Non-Competition	 	19
	 	 	F.	 	Investigation and Agreement by Purchaser; No Other Representations or Warranties	 	20
	 	 	G.	 	Waiver	 	20
	 	 	H.	 	Operating Covenants	 	20
	 	 	I.	 	Notice	 	21
	 	 	J.	 	Existing Guaranties	 	21
	 	 	K.	 	SIMPLE-IRA Indemnity	 	21
	 	 	L.	 	License Agreement Interpretation	 	21
	

V.	
 	

Indemnification	
 	

22
	

 	
 	

A.	
 	

Indemnification by Sellers	
 	

22
	 	 	B	 	Indemnification Procedures	 	22
	 	 	C.	 	Limitation of Sellers' Liability	 	24
	

VI.	
 	

Termination	
 	

26
	

 	
 	

A.	
 	

Termination	
 	

26
	 	 	B.	 	Effect of Termination	 	26
	 	 	C.	 	Confidentiality	 	26
	

VII.	
 	

Dispute Resolution	
 	

27
	

 	
 	

A.	
 	

Dispute Resolution	
 	

27
	 	 	B.	 	Mandatory Arbitration	 	27
	 	 	 	 	 	 	 

i

 

	

VIII.	
 	

Miscellaneous	
 	

28
	

 	
 	

A.	
 	

Expenses, Brokers' and Finders' Fees	
 	

28
	 	 	B.	 	Further Assurances	 	28
	 	 	C.	 	Set-Off	 	29
	 	 	D.	 	Governing Law	 	29
	 	 	E.	 	Modifications, Waivers, Entire Agreement	 	29
	 	 	F.	 	Notices	 	29
	 	 	G.	 	Severability	 	30
	 	 	H.	 	Assignment	 	30
	 	 	I.	 	Third Party Intellectual Property	 	31
	 	 	J.	 	Confidentiality	 	31
	 	 	K.	 	Interpretation	 	31
	 	 	L.	 	Disclosure Schedules	 	31
	 	 	M.	 	Survival	 	32
	 	 	N.	 	Counterparts of the Agreement	 	32

ii

 
DISCLOSURE SCHEDULES  

	Disclosure Schedule III.A.4	 	14
	Disclosure Schedule III.A.5	 	14
	Disclosure Schedule III.A.6	 	14
	Disclosure Schedule III.A.7	 	15
	Disclosure Schedule III.A.10	 	16
	Disclosure Schedule III.A.11	 	16
	Disclosure Schedule III.A.12	 	16
	Disclosure Schedule III.A.13	 	17
	Disclosure Schedule III.A.14	 	17
	Disclosure Schedule III.A.15.a	 	17
	Disclosure Schedule III.A.15.d	 	18
	Disclosure Schedule III.A.16.a(i)	 	18
	Disclosure Schedule III.A.16.a(ii)	 	18
	Disclosure Schedule III.A.17.a(i)	 	19
	Disclosure Schedule III.A.17.a.(ii)	 	19
	Disclosure Schedule III.A.17.b	 	20
	Disclosure Schedule III.A.17.d	 	20
	Disclosure Schedule III.A.17.f	 	20
	Disclosure Schedule III.A.17.g	 	20
	Disclosure Schedule III.A.17.h	 	21
	Disclosure Schedule III.A.18.a	 	21
	Disclosure Schedule III.A.18.b	 	23
	Disclosure Schedule III.A.19	 	23
	Disclosure Schedule III.A.20.b	 	23
	Disclosure Schedule III.A.21	 	24
	Disclosure Schedule III.A.23	 	25
	Disclosure Schedule III.A.25	 	27
	Disclosure Schedule III.A.26	 	27
	Disclosure Schedule III.A.27	 	27
	Disclosure Schedule III.A.29	 	28
	Disclosure Schedule III.A.30	 	28

iii

 
TABLE OF EXHIBITS  

	Exhibit A	 	—	 	Definitions
	Exhibit II.B.6-A	 	—	 	Form of Employment Agreement
	Exhibit II.B.6-B	 	—	 	Form of Consulting Agreements
	Exhibit II.B.7	 	—	 	Assignment of Membership Interest
	Exhibit IV.E.3	 	—	 	Allowed Activities

iv

   PURCHASE AND SALE AGREEMENT  

        THIS PURCHASE AND SALE AGREEMENT ("Agreement") is made as of the 10th day of January, 2007, by and between
Daniel J. Bates ("Bates"), John J. Koleng Jr. ("Koleng"), Feng Zhang
("Zhang"), Michael M. Crowley ("Crowley"), James W. McGinity
("McGinity"), and Robert O. Williams, III ("Williams") (collectively referred to as
"Sellers" and each individually as a "Seller") on the one hand, and LAB International Inc., a
federal Canadian business corporation having its principal place of business at 333 Cote Vestu, Montreal, Canada H4R 2N1 (the
"Purchaser"), on the other hand. (Sellers, on the one hand, and Purchaser, on the other hand, are individually referred to herein as a
"Party" and, collectively, as the "Parties".) 

PREAMBLE  

        A.    Sellers
are the sole members of Formulation Technologies, LLC, a Texas limited liability company, doing business as PharmaForm, L.L.C. and PharmaForm
("Company"). 

        B.    Company
is in the business of research, development, testing and manufacturing of pharmaceutical products and related contract services (the
"Business"). 

        C.    Purchaser
desires to acquire all of Sellers' membership interests in Company (the "Membership Interests") and Sellers
desire to sell and transfer such Membership Interests to Purchaser, subject to the terms and conditions of this Agreement. 

        D.    The
Board of Directors of the Purchaser has approved and adopted this Agreement and the transactions contemplated hereby. 

        E.    Capitalized
terms used in this Agreement shall have the meaning given them or referenced in Exhibit A attached
hereto. 

AGREEMENT  

        For good and valuable consideration, including the mutual representations, warranties and covenants contained herein, the Parties hereto hereby agree as follows: 

I.     PURCHASE AND TRANSFER OF THE MEMBERSHIP INTERESTS  

        A.    Purchase and Transfer of the Membership Interests.    Upon the terms and subject to the conditions contained
herein, and in reliance upon the representations, warranties, assurances and undertakings made herein by each Party to the other Party, Sellers hereby agree to sell and transfer to Purchaser all of
Sellers' Membership Interests of Company, and Purchaser hereby agrees to purchase and accept such transfer. 

        B.    Purchase Price.    The purchase price shall be the cash and stock payable pursuant to this Section I
("Purchase Price"). 

        C.    Payment of Purchase Price at Closing.    The Purchase Price shall be payable as follows: 

        1.    Payment at Closing.    At Closing Purchaser shall deliver to each Seller such Seller's Percentage Interest of a
cash payment of Seven Million Five Hundred Thousand and No/100 Dollars ($7,500,000). 

        2.    Stock Distribution at Closing.    At Closing Purchaser shall distribute to each Seller such Seller's Percentage
Interest of 6,039,535 shares of Purchaser's common stock ("Purchaser Common Stock"), which represents the quotient of (a) Four Million Three
Hundred and Seventy Five Thousand and No/100 Dollars ($4,375,000) and divided by (b) $0.724394, which is the TSX average US dollar share price
for the ten (10) day trading period ending October 25, 2006 (as appropriately adjusted to reflect any stock split, stock dividend, combination, recapitalization, 

1

 

migration
to another stock exchange, merger or similar event after the date hereof, the "Closing Value"). For purposes of this Section I, the US
dollar share price will be calculated based on the average Canadian to US dollar exchange rate as published by the Bank of Canada over the ten (10) business days ending immediately prior to
October 25, 2006, or the date of the occurrence of a Phase I, II, or III Triggering Event, as applicable. 

        D.    Share Issuances and Payments Contingent upon Meeting Milestones.    

        1.    Phase I Distribution.    Promptly after the date that is the later to occur of (i) six months
after the Closing Date or (ii) the date when the Company's First Program reaches Phase I (the "Phase I Triggering Event"),
Purchaser shall distrubute to each Seller (a) such Seller's Percentage Interest of an aggregate number of shares of Purchaser Common Stock equal to the quotient of (i) Four Million Three
Hundred and Seventy Five Thousand and No/100 Dollars ($4,375,000) divided by (ii) the weighted average US dollar share price on the primary
market for the Purchaser Common Stock over the ten (10) trading day period ending on the last trading day immediately prior to the Phase I Triggering Event, and (b) such Seller's
Percentage Interest of One Hundred Thousand and No/100 Dollars ($100,000), payable either in cash or in Purchaser Common Stock (at the price determined by Section I.D.1(a)(ii) above), at
Purchaser's option. If at the Phase I Triggering Event the value of subpart (a)(ii) above is below 70% or above 130% of the Closing Value, the
value of subpart (a)(ii) above shall instead equal 70% or 130% of the Closing Value, respectively. For purposes of this Section I.C.,
"First Program" means any proprietary non-inhalation product developed out of Company and
"Phase I" means that an Investigational New Drug Application ("IND") dossier is filed with the
FDA, and the Parties do not receive any adverse action from the FDA within thirty (30) days after filing. 

        2.    Phase II Distribution.    Promptly after the date of the Phase II Triggering Event, Purchaser
shall distribute to each Seller (a) such Seller's Percentage Interest of an aggregate number of shares of Purchaser Common Stock equal to the quotient of (i) Four Million Three Hundred
and Seventy Five Thousand and No/100 Dollars ($4,375,000) divided by (ii) the average US dollar share price on the primary market for the
Purchaser Common Stock over the ten (10) trading day period ending on the last trading day immediately prior to the Phase II Triggering Event, and (b) such Seller's Percentage
Interest of One Hundred Thousand and No/100 Dollars ($100,000), payable either in cash or in Purchaser Common Stock (at the price determined by Section I.D.2(a)(ii) above), at Purchaser's
option. If at the Phase II Triggering Event the value of subpart (a)(ii) above is below 60% or above 140% of the Closing Value, the value
of subpart (a)(ii) above shall instead equal 60% or 140% of the Closing Value, respectively. "Phase II Triggering
Event" means that Company's Gross Revenue within the first twelve months after January 1, 2007, equals or exceeds ten million dollars ($10,000,000), or, within the first
eighteen months after January 1, 2007, equals or exceeds fifteen million dollars ($15,000,000), or within the first twenty
four months after January 1, 2007, equals or exceeds twenty million dollars ($20,000,000). "Gross Revenue" means the total gross amount invoiced
directly by PharmaForm to third parties for goods, services or licensing, before: (a) trade and reasonable and customary cash discounts; (b) refunds, rebates, retroactive price
adjustments and any other allowances that effectively reduce the invoiced amount; (c) returns, credits and allowances; and (d) freight, taxes and insurance, but excludes all amounts
invoiced or revenue received by Company from business conducted between Company and Purchaser, Purchaser's successors or assigns, or Purchaser's Affiliates other than Company;  provided, however, that: 

        a.     to
the extent reasonably available, determination of Gross Revenue shall be based on Company's audited year-end financials; 

        b.     Purchaser
shall not materially change Company's current invoicing policies and procedures, unless required by GAAP; and 

2

 

        c.     If
Company signs a contract with a third party to provide services or products to such third party and reasonably anticipates a profit margin from such contract within
the range of the profit margins typically realized by Company from similar contracts, and work to be performed by Company for Purchaser or its Affiliates causes Company to be unable to perform under
such contract, then the revenue that would have been reasonably anticipated from such contract in the absence of interfering work from Purchaser or its Affiliates will be included in the determination
of Gross Revenue. 

        3.    Phase III Distribution.    Promptly after the date that occurs the later of (i) eighteen
(18) months after the Closing Date or (ii) (A) the date any proprietary non-inhalation EDACS or other similar abuse deterrent product developed out of Company under a
patent (or patent application) proprietary to Company completes the first Phase III clinical study or the date Company enters into a binding contractual arrangement with a third party to
manufacture or commercialize a non-inhalation EDACS or other similar abuse deterrent product under a patent (or patent application) proprietary to Company, or (B) the date of
issuance to Company by the United States Patent and Trademark Office, with regard to a Company patent (or patent application) of a non-inhalation EDACS or other similar abuse deterrent
product, of a notice of allowability of claims and with scope of claims that is reasonably likely to allow Company to develop, produce and market a non-inhalation EDACS or other similar
abuse deterrent product under such patent (the "Phase III Triggering Event"), Purchaser shall distribute to each Seller (a) such Seller's
Percentage Interest of an aggregate number of shares of Purchaser Common Stock equal to the quotient of (i) Four Million Three Hundred and Seventy Five Thousand and No/100 Dollars ($4,375.000)  divided by (ii) the average US dollar share price on the primary market for the Purchaser Common Stock over the ten (10) trading day
period ending on the last trading day immediately prior to the Phase III Triggering Event, and (b) such Seller's Percentage Interest of One Hundred Thousand and No/100 Dollars
($100,000), payable either in cash or in Purchaser Common Stock (at the price determined by Section I.D.3(a)(ii) above), at Purchaser's option. If at the Phase III Triggering Event the
value of subpart (a)(ii) above is below 30% or above 170% of the Closing Value, the value of  subpart (a)(ii) above shall instead equal 30% or
170% of the Closing Value, respectively. 

        4.    Termination of Obligations.    On and after the date that occurs sixty (60) months from the Closing Date,
the obligations of Purchaser under this Section I.D shall terminate and thereafter be of no further force or effect. 

        E.    Additional Purchase Price Covenants.    

        1.    Purchaser Common Stock.    Purchaser shall maintain a sufficient number of duly created, allotted and reserved
shares of Purchaser Common Stock for issuance to the Sellers pursuant hereto. If at any time the issued and outstanding Purchaser Common Stock is subject to a stock split, dividend, combination,
recapitalization, merger or similar event, then "Purchaser Common Stock" shall mean the securities and other cash or property issued, granted, dividended or exchanged for the outstanding Purchaser
Common Stock, and the number of shares of Purchaser Common Stock allotted and reserved for issuance to Sellers shall be appropriately adjusted. Purchaser shall comply with the requirements of all
applicable corporate and securities Laws in relation to the issuance and trading of its securities. For so long as the Purchaser Common Stock is listed for trading on a stock exchange or quotation
system, Purchaser shall (i) remain a reporting issuer in good standing on such exchange or system and (ii) subject to applicable securities Laws, use commercially reasonable efforts to
allow the Purchaser Common Stock issued to the Sellers hereunder to be traded on such exchange or system (including making the appropriate filings to have such stock approved for listing on the TSX,
if applicable). 

3

 

        2.    Sellers' Put Option.    Subject to applicable law, if at any time Purchaser fails to (i) have the
Purchaser Common Stock listed and posted for trading on the TSX, on Nasdaq or another nationally recognized United States stock exchange (not including any over the counter trading system or the pink
sheets) or, if none of the foregoing is commercially reasonable, on an internationally recognized stock exchange or trading system of similar standing
(provided, that the Purchaser Common Stock may become unlisted or posted on a temporary basis in connection with its becoming listed on another such
exchange or trading system), or (ii) use commercially reasonable efforts to have the Purchaser Common Stock listed for trading on Nasdaq or another nationally recognized United States stock
exchange (not including any over the counter trading system or the pink sheets) within a reasonable time after Closing, then any Seller may elect to sell to Purchaser all Purchaser Common Stock issued
to such Seller hereunder for cash within 180 days from the Seller's becoming aware of the occurrence of Purchaser's failure under item (i) or (ii) of this
subparagraph I.E.2 above. If, upon the next issuance of Purchaser Common Stock (and upon any subsequent issuance of Purchaser Common Stock), if any, Purchaser is not in compliance with
items (i) or (ii) above, then any Seller may elect to sell to Purchaser all such Purchaser Common Stock for cash within 180 days from the issuance of such Purchaser Common Stock. Each
Seller may make such election by giving written notice to Purchaser stating the failure giving rise to such election and the date upon which the sale is to occur, which date may not be sooner than ten
(10) Business Days after such notice. On the date stated in such notice, such Seller shall surrender to
Purchaser all applicable certificates representing such Purchaser Common Stock, free and clear of all Liens, and Purchaser shall pay to such Seller an amount in cash for each surrendered share of
Purchaser Common Stock equal to the Closing Value or other applicable value given to such share pursuant to Section I above. At the election of a Seller, all shares of Purchaser Common Stock to
be issued to such Seller after the date stated in such notice shall instead be paid in cash at the applicable issue price under Section I.C or I.D above. 

        3.    Repurchase Right.    If at any time Sellers, their successors or assigns, (the "Sellers
Group") collectively own 20% or more of the issued and outstanding shares of Purchaser Common Stock as a result of an issuance of Purchaser Common Stock hereunder, then
Purchaser shall have the right, but not the obligation, to purchase from the Sellers Group on a pro rata basis the fewest number of shares of Purchaser Common Stock required to reduce the total number
of shares of Purchaser Common Stock owned by Seller's Group to less than twenty percent (20%) of the issued and outstanding shares of Purchaser Common Stock. The price at which Purchaser may purchase
and Sellers shall sell such shares of Purchaser Common Stock shall be the price used to determine the number of shares most recently issued to Sellers. 

        4.    Alternative to Distribution of Company Common Stock.    If the value of subpart I.D.1(a)(ii),
I.D.2(a)(ii) or I.D.3(a)(ii) is determined based on the lower percentage of the Closing Value, as set forth in the second sentence of Section I.D.1, I.D.2 or I.D.3, respectively, Purchaser
shall have the right, but not the obligation, to pay part or all of the respective $4,375,000 installment in cash instead of Purchaser Common Stock. 

        F.    Manner of Payments.    Unless otherwise specified herein, all cash payments contemplated under this Agreement
shall be made in United States dollars and all references to $ or Dollars herein refer to United States dollars. 

        G.    Transfer of Title.    The full and unencumbered ownership and title to the Membership Interests shall pass from
Sellers to Purchaser at the Closing simultaneously with the fulfillment and completion of the Closing procedures as set forth in Section II below. 

4

 

II.    CLOSING  

        A.    Closing.    The closing of the transaction contemplated by this Agreement (the
"Closing") shall take place at the offices of McGinnis, Lochridge & Kilgore, LLP, 600 Congress Avenue, Suite 2100, Austin, Texas, on
January 26, 2007, or as soon thereafter as the conditions precedent set forth in Sections II.B and II.C have been satisfied or waived, as of the close of business on such date, or at
such other date, time or place as Sellers and Purchaser may mutually agree ("Closing Date"). The parties recognize and agree that all items of income,
gain, loss, deduction and credit of the Company from January 1, 2007 through and including the end of the day on the Closing Date (other than items resulting from actions taken by Purchaser or
the Company on the Closing Date not in the ordinary course of business) shall be reported by the Company on its final U.S. federal income tax return on Form 1065 for the period ending on the
Closing Date (which such return shall be prepared by Sellers), with the Schedules K-1 contained therein allocating such items to the Sellers, who shall report such income on their
individual U.S. federal income tax returns within which the Closing Date occurs. All items of income, gain, loss, deduction and credit of the Company from and after the beginning of the day after the
Closing Date shall be reported in a manner appropriate to the status of the Company being wholly owned by Purchaser, and in no event shall any of such items be allocated to any of the Sellers. 

        B.    Conditions Precedent to the Obligations of Purchaser.    The obligations of Purchaser under this Agreement to
effect the Closing are subject to the satisfaction in all material respects or waiver by Purchaser prior to or on the Closing Date of each of the following conditions: 

        1.    Accuracy of Representations and Warranties.    The representations and warranties of Sellers contained in this
Agreement, in any Schedule or Disclosure Schedule hereto or in any closing document delivered by the Sellers to Purchaser pursuant hereto shall be true and correct at the time of execution of this
Agreement and and as of the Closing Date as though made at and as of that time other than such representations and warranties as are specifically made as of another date;  provided, that this condition
shall be deemed to have been satisfied unless the individual or aggregate impact of all inaccuracies of such
representations and warranties would be reasonably likely to have a Material Adverse Effect. Purchaser shall have received a certificate signed by each Seller to such effect. 

        2.    Compliance with Covenants.    Sellers shall have performed and complied in all material respects with all
covenants of this Agreement to be performed or complied with by Sellers at the Closing. 

        3.    Legal Actions or Proceedings.    No legal action or Proceeding shall have been instituted after the date hereof
against Sellers or Purchaser, arising by reason of the acquisition of the Membership Interests pursuant to this Agreement, which is reasonably likely (i) to restrain, prohibit or invalidate the
consummation of the Contemplated Transactions, (ii) to have a Material Adverse Effect or (iii) to have a material adverse effect on the results of the operations or financial condition
of Purchaser and its Affiliates, taken as a whole, after giving effect to the consummation of the Contemplated Transactions. 

        4.    New Information.    From or after the date hereof, Purchaser shall not have become aware of any event, change or
circumstance that would be a Material Adverse Effect. 

        5.    Sale Notice.    The Managers of Company shall have given notice in compliance with Section 2.06 of the
Amended and Restated Regulations of Company. 

        6.    Employment/Consulting Agreements.    The Key Employees shall have executed and delivered to Purchaser employment
agreements substantially in the form of Employment Agreement attached hereto as Exhibit II.B.6-A ("Employment
Agreement"), and the Key Consultants shall have executed and delivered to Purchaser consulting agreements substantially in the form of Consulting Agreement attached hereto as  Exhibit II.B.6-B ("Consulting Agreements"). 

5

  

        7.    Assignment of Membership Interest.    Each Seller shall have executed and delivered to Purchaser Assignments of
Membership Interest substantially in the form of the Assignment of Membership Interest attached hereto as Exhibit II.B.7
("Assignment of Membership Interest"). 

        8.    Authorizations.    Sellers shall have obtained all necessary authorizations, approvals and consents required to
be obtained by Sellers or Company for the lawful and valid consummation of the Contemplated Transactions. 

        9.    Resignations.    Company shall have received written resignations from all members of the Company's Board of
Managers from their positions as managers (the "Resignations"). 

        10.    Estoppel Certificate.    Purchaser shall have received an estoppel certificate executed by the landlord of the
Leased Property. 

        C.    Conditions Precedent to the Obligations of Sellers.    The obligations of Sellers under this Agreement are
subject to the satisfaction in all material respects or waiver by Sellers prior to or on the Closing Date of each of the following conditions: 

        1.    Accuracy of Representations and Warranties.    The representations and warranties of Purchaser contained in this
Agreement or in any closing certificate or document delivered by Purchaser to Sellers pursuant hereto shall be true and correct at the time of execution of this Agreement and as of the Closing Date as
though made at and as of that date other than such representations and warranties as are specifically made as of another date. Sellers shall have received a certificate signed by duly authorized
representatives of Purchaser to such effect. 

        2.    Compliance with Covenants.    Purchaser shall have performed and complied with all covenants of this Agreement
to be performed or complied with by Purchaser at the Closing Date. 

        3.    Legal Actions or Proceedings.    No legal action or Proceeding shall have been instituted after the date hereof
against Sellers or Purchaser, arising by reason of the acquisition of the Membership Interests pursuant to this Agreement, which is reasonably likely (i) to restrain, prohibit or invalidate the
consummation of the Contemplated Transactions, (ii) to have a Material Adverse Effect or (iii) to have a
material adverse effect on the results of the operations or financial condition of Purchaser and its Affiliates, taken as a whole, after giving effect to the consummation of the Contemplated
Transactions. 

        4.    Authorizations.    Purchaser shall have obtained all necessary authorizations, approvals and consents from all
Governmental and Regulatory Authorities required to be obtained by Purchaser for the lawful and valid consummation of the Contemplated Transactions. 

        D.    Closing Actions.    

        1.    Seller's Actions at Closing.    At Closing, Sellers shall: 

        a.     deliver
to Purchaser Assignments of Membership Interest executed by each Seller; 

        b.     deliver
to Purchaser Employment Agreements executed by each Key Employee; 

        c.     deliver
to Purchaser Consulting Agreements executed by each Key Consultant; 

        d.     deliver
to Purchaser the Company's books and records; 

        e.     deliver
to Purchaser the Resignations; and 

        f.      deliver
to Purchaser the Certificate required under Section II.B.1. 

6

 

        2.    Purchaser's Actions at Closing.    At Closing, Purchaser shall 

        a.     deliver
to each Seller such Seller's Percentage Interest of a cash payment of Seven Million Five Hundred Thousand and No/100 Dollars ($7,500,000) by cashier's check or
wire transfer to an account designated by such Seller at least three (3) days prior to Closing; 

        b.     each
Seller such Seller's Percentage Interest of 6,039,535 shares of Purchaser Common Stock in accordance with the provisions of Section I.C.2 above; and 

        c.     deliver
to Sellers the Certificate required under Section II.C.1. 

III.  REPRESENTATIONS AND WARRANTIES  

        A.    Sellers' Representations and Warranties.    Each Seller acknowledges that Purchaser is entering into this
Agreement in reliance on the representations and warranties given herein by Sellers to Purchaser being true and correct. As of the date hereof and as of the Closing, Sellers hereby represent and
warrant to Purchaser as follows: 

        1.    Organization and Existence.    Company is a Texas limited liability company duly organized, validly existing,
and in good standing under the laws of its jurisdiction of organization, with full power and authority to own and operate the Business as it is now being owned and operated. Company neither owns nor
controls any subsidiary nor is engaged in a partnership, joint venture, business trust or similar entity that is engaged in the Business. 

        2.    Authority and Approval.    Each Seller has the power to enter into this Agreement and each of the Related
Agreements to which it is a Party and to perform its obligations under this Agreement and any such Related Agreements. The execution, delivery and performance by each Seller of this Agreement and the
Related Agreements to which it is to be a Party, and the consummation by each Seller of the transactions contemplated in this Agreement and any such Related Agreements, have been duly authorized by
all required action on the part of each Seller. This Agreement has been duly executed and delivered by each Seller, and, when executed and delivered by the applicable Seller, the Related Agreements to
which any Seller is to be a Party will have been duly executed and delivered by such Seller. This Agreement, assuming due and valid execution and delivery by Purchaser, is, and each of the Related
Agreements to which each Seller is to be a Party when executed and delivered by each Seller will be, the valid and binding obligations of each Seller enforceable against each Seller in accordance with
their respective terms. 

        3.    Capital Structure.    Sellers own one hundred percent (100%) of the issued and outstanding Membership Interests
of the Company. All such Membership Interests were validly issued and are fully paid and nonassessable and at the Closing will be free from any prescriptive rights, restrictions, pledges, liens,
encumbrances, rights, titles and interests of others, other than restrictions imposed under state or federal securities laws. Company has neither issued nor authorized any other classes or series of
Membership Interests. Neither Company nor any Seller nor any other Person has any convertible debentures or notes, other securities, or rights, warrants, options, commitments or other agreements with
respect to any Membership Interests or other securities of Company, authorized, offered, committed, issued or outstanding. There are no voting trusts, proxies or other agreements or understandings
with respect to the voting of any 

7

 

Membership
Interests of the Company. At Closing, the Membership Interests of Company shall be owned by Sellers as indicated below: 

	Name:
 
	 	Percentage of Ownership:
	 
	Bates	 	03.0000	 
	Koleng	 	06.7900	 
	Zhang	 	06.7900	 
	Crowley	 	02.9100	 
	McGinity	 	40.2550	 
	Williams	 	40.2550	 
	Total:	 	100.0000	 percent

        4.    No Conflict.    Except as set forth on Disclosure Schedule III.A.4, the execution and delivery by each
Seller of this Agreement and each of the Related Agreements to which it is to be a Party, and each Seller's compliance with the terms and conditions hereof and thereof, and the consummation by each
Seller of the transactions contemplated hereby and thereby, do not and will not (i) require of Sellers the consent of any Person, (ii) violate any provision of, or require any consent,
authorization, or approval under, any Law or Order applicable to it, (iii) violate, conflict with, result in a Breach of, constitute a default under (whether with or without notice or the lapse
of time or both), accelerate or permit the acceleration of the performance required by, or require any consent, authorization, or approval under, any Material Contract or Permit to which Company is a
Party or by which Company is bound or to which any of the Assets is subject, or (iv) result in the creation of any Lien upon the Assets. 

        5.    Governmental Approvals and Filing.    Except as set forth on Disclosure Schedule III.A.5, no consent,
authorization, approval or action of, filing with, notice to, or exemption from any Governmental or Regulatory Authority on the part of any Seller is required in connection with the execution,
delivery and performance of this Agreement or any Related Agreements to which any Seller is to be a Party or to consummate the transactions contemplated hereby or thereby. 

        6.    Title.    Company owns no real property. Company has good title to, or holds pursuant to valid and enforceable
leases, all of the personal property reflected in the Financial Statements (the "Assets"); to the extent required by GAAP, the assets of the Company as
of October 31, 2006 are reflected in the Financial Statements; and except for Permitted Liens or as otherwise set forth on Disclosure Schedule III.A.6, all of the Assets are free and
clear of any liens, charges, pledges, security interests or other encumbrances (including tax liens), except for current year ad valorem tax liens. Each item comprising the Assets is in good repair
and operating condition, reasonable wear and tear excepted, and is suitable for the purpose for which it is presently being used. 

        7.    Real Property.    Disclosure Schedule III.A.7 lists and describes briefly all real property leased or
subleased to Company. Seller has delivered or made available to Buyer correct and complete copies of the Leases (as amended to date) listed in Disclosure Schedule III.A.7
("Leases"). Except as disclosed in Schedule III.A.7, with respect to each Lease listed in Schedule III.A.7: 

        a.     the
Lease is legal, valid, binding, enforceable against Company and is in full force and effect; 

        b.     Seller
is not in breach or default of the Lease, and to the Knowledge of Seller, no event has occurred that, with notice or the passage of time, or both, would constitute
a breach or default of the Lease by Seller or permit termination, modification, or acceleration thereunder by landlord; 

8

 

        c.     there
are no material disputes, oral agreements or forbearance programs in effect as to the Lease; 

        d.     except
as set forth in Disclosure Schedule III.A.7, Seller has not assigned, transferred, conveyed, mortgaged, deeded in trust or encumbered any interest in the
Lease; 

        e.     all
facilities subject to the Lease are supplied with utilities and other services necessary for the operation of said facilities and equipment. 

        8.    Solvency and Related Matters.    Each Seller will be Solvent immediately after the Closing Date, after giving
effect to (a) the transactions contemplated in this Agreement and (b) any other transactions contemplated by Sellers or any of their representatives on or after the Closing Date which
would be taken into account in determining whether any of the transactions contemplated hereby were invalid or illegal under, in violation of, or can be set aside or give rise to any award or damages,
sanctions or other Liability against Purchaser or any of its Affiliates or representatives under, applicable bankruptcy, fraudulent conveyance, fraudulent transfer or other similar Laws. 

        9.    Illegal Payments.    No Seller nor, to the Knowledge of Sellers, any of their respective partners, directors,
officers or managers, nor, to the Knowledge of Sellers, any officer, manager or employee of Company, has (a) used any Company funds for unlawful contributions, gifts, entertainment, or other
unlawful expenses relating to political activity, (b) made any unlawful payments on behalf of the Company to foreign or domestic government officials or employees or to foreign or domestic
political parties or campaigns from corporate funds, or (c) violated in any material respect the Foreign Corrupt Practices Act of 1977. 

        10.    Brokers.    Except as set forth on Disclosure Schedule III.A.10, no broker, finder or investment banker
is entitled to any brokerage commission, finder's fee or similar payment in connection with the transactions contemplated hereby based upon arrangements made by or on behalf of Sellers. 

        11.    Legal Proceedings.    Except as set forth on Disclosure Schedule III.A.11, there are no actions, suits
or Proceedings with respect to the Company or the Business pending at law or in equity, or before or by any Governmental or Regulatory Authority or by any Person, which, individually or in the
aggregate could reasonably be expected (i) to have a Material Adverse Effect, or (ii) to prevent the consummation of the Contemplated Transactions; nor, to the Knowledge of Sellers, are
any such actions, suits or Proceedings with respect to the Company or the Business threatened against Company. 

        12.    Financial Statements.    Included in Disclosure Schedule III.A.12 are Company's statements of assets,
liabilities and members' equity-modified cash and related statements of revenues, expenses and retained earnings-modified cash for the fiscal years ended December 31, 2004 and
December 31, 2005 ("Year-End Financial Statements") and Company's Interim Balance Sheet. The Year-End Financial
Statements and the Interim Balance Sheet are hereinafter referred
to as the "Financial Statements." The Financial Statements are based upon the financial books and records of Company and have been prepared on a basis
consistent with Company's past practice. The Financial Statements fairly present in all material respects the financial position, results of operations and cash flows of Company as of the dates and
periods therein indicated. 

        13.    Undisclosed Liabilities.    Disclosure Schedule III.A.13 sets forth a list of all liabilities of Company
required to be presented in unaudited interim financial statements prepared in conformity with GAAP, if any, to the Knowledge of Sellers that are not reflected or reserved against on the Interim
Balance Sheet. 

        14.    Accounts Receivable.    Except as set forth on Disclosure Schedule III.A.14, all accounts receivable of
the Company reflected on the Interim Balance Sheet are valid receivables subject to 

9

 

no
setoffs or counterclaims net of the applicable reserve for bad debts shown on the Interim Balance Sheet. All accounts receivable reflected in the financial or accounting records of the Company that
have arisen since the most recent fiscal quarter end are valid receivables subject to no setoffs or counterclaims net of the applicable reserve for bad debts in an amount proportional to the reserve
shown on the most recent balance sheet included in the Financial Statements. 

        15.    Employee Benefit Plans.    

        a.     Disclosure
Schedule III.A.15.a lists all programs, plans and arrangements that are provided to or for the benefit of the current or former employees of the
Company, including (i) any collective bargaining agreement and any written employment agreement, not terminable upon sixty (60) days notice without penalty, (ii) each employee
pension benefit plan (as defined in ERISA, section 3(2), hereinafter "Employee Pension Benefit Plan"), defined benefit, defined contribution,
stock option, stock ownership, executive compensation, bonus, incentive compensation, qualified and non-qualified deferred compensation, and profit-sharing plan, program or arrangement,
(iii) each employee welfare benefit plan (as defined in ERISA, section 3(1), hereinafter "Employee Welfare Benefit Plan"), medical,
dental, vision, disability or death benefit plan, program or arrangement, and (iv) any vacation, holiday, sick leave, cafeteria, health savings account, flexible spending account, fringe
benefit, severance, supplemental unemployment benefit, group life insurance, other insurance, and voluntary employee beneficiary association (VEBA) plan, program or arrangement, in each case that is
sponsored, maintained, contributed to or required to be contributed to by Company and that covers current or former employees (such programs, plans and arrangements described in clause (ii),
(iii) and (iv) above being referred to herein as the "Employee Benefit Plans"). True and complete copies of the Employee Benefit Plans listed in
Disclosure Schedule III.A.15.a have been delivered to Purchaser. 

        b.     Neither
the execution nor delivery of this Agreement, nor the consummation of the transactions contemplated by this Agreement, whether alone or together with another
event, including but not
limited to termination of employment, will result in any Liability to Purchaser or in any payment (including any bonus, deferred compensation, golden parachute or severance payment), or increase the
benefits payable in any Employee Benefit Plan. 

        c.     No
Employee Benefit Plan is a Multiemployer Plan (as such term is defined in Section 3(37) or Section 4001(a)(3) of ERISA). 

        d.     Except
as set forth in Disclosure Schedule III.A.15.d, Company has not incurred (nor has any event occurred which reasonably could be anticipated to result in any
Seller incurring) any material loss in connection with any existing or previously existing Employee Benefit Plan that could become, on or after the Closing Date, an obligation or Liability of
Purchaser or the Company. 

        16.    Employee Matters.    

        a.     Disclosure
Schedule III.A.16.a(i) lists all current Company employees as of December 1, 2006 and their hourly rates of compensation, base salaries and bonus
arrangements (as applicable). In addition, to the extent any current employees of Company are on leaves of absence as of December 1, 2006, Disclosure Schedule III.A.16.a(ii) indicates
the nature of such leave of absence and each such employee's anticipated date of return to active employment. To the Knowledge of Sellers, Company currently complies in all material respects and for
the past sixty (60) months has continuously complied in all material respects with all Laws relating to the hiring and employment of workers, including, but not limited to, Laws relating to the
classification of workers, wages, hours, overtime, employment taxes, equal 

10

 

opportunity,
non-discrimination, medical leave, military leave, immigration and collective bargaining and with all Laws governing occupational health and safety. 

        b.     (1)
Company is not delinquent in payments to, or on behalf of, any employees for any wages, salaries, commissions, bonuses or other direct compensation for any services
performed by them to date or amounts required to be reimbursed to such employees; (2) Company is not delinquent in payments of any employment taxes on behalf of any employees with respect to
services; (3) there is no unfair labor practice complaint against Company with respect to employees of the Company pending before the National Labor Relations Board or any other Governmental or
Regulatory Authority; (4) there is no labor strike, material dispute, slowdown or stoppage actually pending or, to the Knowledge of Sellers, threatened against the Company; (5) there has
been no charge of discrimination filed or, to the Knowledge of Sellers, threatened, against Company with the Equal Employment Opportunity Commission or similar Governmental or Regulatory Authority;
and (6) there is no pending or, to the Knowledge of Sellers, threatened administrative or judicial proceeding or investigation under the Fair Labor Standards Act, the Family and Medical Leave
Act, the Occupational Safety and Health Act, the
National Labor Relations Act, ERISA, the Code, or any other federal or state law relating to Company's employees. 

        17.    Intellectual Property.    

        a.     Disclosure
Schedule III.A.17.a(i) lists all patents owned by Company (the "Company Patents"). Disclosure
Schedule III.A.17.a(ii) lists all patents owned by a third party and licensed for use by Company ("Licensed Patents"). The Company Patents and
the Licensed Patents (collectively, the "Patents") are all the Patents used by the Company in the Business. 

        b.     Disclosure
Schedule III.A.17.b lists all trademarks and tradenames owned by Company (the "Trademarks"). The
Trademarks are all the trademarks and tradenames used by the Company in the Business. 

        c.     The
Company owns or has licensed rights to the Patents and Trademarks sufficient to permit the operation of the Business as now being conducted. To the Knowledge of
Sellers, no Patents or Trademarks are subject to any outstanding order, judgment, lien, encumbrance or attachment. To the Knowledge of Sellers, there are no pending or threatened proceedings,
litigation or other adverse claims affecting any Patents or Trademarks and, to the Knowledge of Sellers, no person or entity is infringing Company's rights to the Patents or Trademarks. 

        d.     Disclosure
Schedule III.A.17.d lists all Company applications for registered patents, trademarks, trade names, service marks and copyrights. 

        e.     To
the Knowledge of the Sellers, the Company is not in violation or infringement of any patent, patent license, trade name, trademark, servicemark, brandmark, brand name,
copyright, know-how or other proprietary or trade rights of any third party; and to the Knowledge of Sellers there is no non-frivolous basis for any such claims. 

        f.      Disclosure
Schedule III.A.17.f. identifies any Patents and Trademarks with regard to which Company has granted rights to any other Person. 

        g.     Disclosure
Schedule III.A.17.g identifies all of Company's software licenses ("Software Licenses"). 

11

  

        h.     Except
as set forth in Disclosure Schedule III.A.17.h, to the Knowledge of Sellers: 

            i.  No
Patents or Trademarks or application for Patents or Trademarks have lapsed, expired, been finally abandoned, been disclaimed, been withdrawn, been the subject of a
final judgment of invalidity by any court of competent jurisdiction, been the subject of a final judgment of unenforceability by any court of competent jurisdiction, been the subject of any holding or
declaration of unenforceability, invalidity, or refused to be reissued by any domestic or foreign governmental agency, including, without limitation, the United States Patent and Trademark Office, or
been canceled within the past 12 months; 

           ii.  No
unresolved written claim or contest, opposition, invalidation or cancellation Proceeding has been asserted by any Person (1) against the use by Company of any
Patents or Trademarks or (2) challenging the ownership or validity of any of the Patents or Trademarks; 

          iii.  Company
is the owner of good title to or is the licensee of intellectual property sufficient to conduct the Business as now conducted; 

          iv.  No
use by another Person infringes on any of the Patents or Trademarks. 

           v.  There
are no royalty payments, fees or other obligations of Company to any other Person with regard to Patents and Trademarks. 

        18.    Material Contracts.    

        a.     Disclosure
Schedule III.A.18.a contains a true and correct list of all of the following Contracts to which Company is a Party, other than Leases
("Material Contracts"): 

            i.  each
Contract involving a commitment to others to make capital expenditures in excess of $10,000; 

           ii.  written
employment, confidentiality, non-competition, severance or termination agreements as to employees and consultants; 

          iii.  all
Contracts relating to indebtedness for borrowed money of Company (including, without limitation, loan agreements, lease purchase arrangements, guarantees,
agreements to supply funds or other undertakings on which others rely in extending credit), or any conditional sales contracts, chattel mortgages, equipment lease (financing) agreements and other
security arrangements with respect to personal property; 

          iv.  all
Contracts with any Seller or Affiliate of Company; 

           v.  all
Contracts that limit the freedom of Company to compete with any Person in any area or territory; 

          vi.  all
Contracts (whether exclusive or otherwise) with any sales agent, representative, franchisee, dealer, distributor or warehouse; 

         vii.  all
Contracts that require the payment of royalties; 

        viii.  all
Contracts with any Government or Regulatory Authority; 

          ix.  all
Contracts involving a sharing of profits, losses, costs or liabilities; 

           x.  all
written supply agreements (other than purchase orders) with a customer of Company for the sale to the customer of Products and, if not written, then Company term
sheets that govern the customer relationship and associated terms and conditions; 

          xi.  all
written vendor agreements (other than purchase orders) with the suppliers identified in Disclosure Schedule III.A.27 and Company's standard purchase order
forms. 

12

 

        b.     True
and correct copies of the Material Contracts listed in Disclosure Schedule III.A.18.a have been delivered to Purchaser. Except as otherwise disclosed in
Disclosure Schedule III.A.18.b, each listed Material Contract is in full force and effect and is valid, binding and enforceable against the Company in accordance with its terms. Except as set
forth in Disclosure Schedule III.A.18.b, to the Knowledge of Sellers, no material default exists on the part of Company under any of the Material Contracts. 

        19.    Permits.    Company owns or possesses all Permits material to the operation of the Business as presently
conducted. Disclosure Schedule III.A.19. identifies all Permits possessed by Company that are material to the operation of the Business as conducted on the date of this Agreement. All such
Permits possessed by Company are in full force and effect; Company has complied in all material respects with the terms and conditions of such Permits; and Company has not received notice of violation
or proposed revocation or termination of any such Permit from any Governmental or Regulatory Authority. 

        20.    Insurance.    

        a.     Company
maintains insurance covering the Business and the Assets in amounts (and subject to deductibles and self-insurance amounts) deemed adequate by
Company. All such insurance is in full force and effect, all premiums due under such insurance up to the date hereof have or will be paid and no written notice of cancellation or termination has been
received with respect to any such insurance. 

        b.     Except
as set forth on Disclosure Schedule III.A.20.b, there are no insurance claims for casualty losses to any of the Assets as of the date hereof. 

        21.    Environmental Matters.    The sole representations and warranties with respect to environmental matters are set
forth in this Section III.A.21. Except as set forth in Disclosure Schedule III.A.21: 

        a.     To
Sellers' Knowledge, Company holds, and is in compliance in all material respects with, all Permits required by Company under any Environmental, Health and Safety Laws
to conduct the Business as currently being conducted. Company has not received notice of violation or proposed revocation or termination of any such Permit from any Governmental or Regulatory
Authority (which has not been resolved). 

        b.     Neither
Company nor any Seller has received any written request for information or any written notice that Company is a potentially responsible Party under any
Environmental, Health and Safety Laws with regard to the Company's Leased Real Property. 

        c.     Company
is not subject to any outstanding Order relating to non-compliance with any Environmental, Health and Safety Law or to investigation or cleanup of
regulated substances under any Environmental, Health and Safety Law. 

        d.     Company
does not operate any underground storage tanks at any of the Company's Leased Real Property. 

        e.     Company
has not transported, stored, used, released, disposed of, manufactured or sold Hazardous Materials in violation of any Environmental, Health and Safety Law at or
from any of the Company's Leased Real Property. 

        f.      To
Sellers' Knowledge, Company has not disposed of, transported, manufactured or sold any goods or Products containing a Hazardous Material in violation of any
Environmental, Health and Safety Law. 

        g.     Company
has never commissioned any environmental assessment with repect to any of the Company's Leased Real Property 

13

 

        h.     Company
has disposed of all hazardous waste it has generated, other than the hazardous waste it currently holds on site under the applicable accumulation time
rule 30 TAC §335.69 and/or 40 CFR §262.34, in accordance with all applicable laws and regulations. 

        22.    Payment of Taxes; Tax Liens.    

        a.     Company
has (A) duly and timely filed all Tax Returns required to have been filed and (B) timely paid all Taxes for which it is or may be liable and which
have become due and payable. Company has timely and properly withheld or collected, paid over and reported all Taxes required by any Governmental or Regulatory Authority to be withheld or collected by
Company on or before the date hereof. 

        b.     Company
has received no notice of any kind that any authority has asserted any adjustment that could result in an additional Tax for which Company is or may be liable.
Company has received no notice of any kind of any audit, examination, investigation, dispute, proceeding or claim (collectively, "Tax Proceeding")
relating to any Tax for which Company is or may be liable. No statute of limitations with respect to any Tax for which Company is or may be liable has been waived or extended and has
not expired. Company is not a Party to any Tax sharing or Tax allocation agreement, arrangement or understanding. 

        c.     Company
has no "tax-exempt use property" within the meaning of Section 168(h) of the Code. None of the assets of Company is required to be treated as
being owned by any other person pursuant to the "safe harbor" leasing provisions of Section 168(f)(8) of the Internal Revenue Code of 1954, as in effect prior to the repeal of said leasing
provisions. 

        23.    No Material Adverse Effect.    Since the date of the Interim Balance Sheet, to the Knowledge of Sellers, there
not has been a Material Adverse Effect. As of the date hereof, since the date of the Interim Balance Sheet, and except as set forth on Disclosure Schedule III.A.23: 

        a.     Company
has carried on the Business in the Ordinary Course of Business; 

        b.     Company
has not, except in the Ordinary Course of Business, sold, leased, transferred, or assigned any of the properties, rights or other assets of the Company that
would, but for such transaction, be Assets; 

        c.     Company
has not cancelled, compromised, waived or released any right or claim (or series of related rights and claims) involving more than $25,000 in the aggregate
outside the Ordinary Course of Business; 

        d.     Company
has not granted any license or sublicense of any rights under or with respect to any Patents or Trademarks or terminated any license or sublicense with respect to
any Patents or Trademarks; 

        e.     Company
has not entered into any employment contract or collective bargaining agreement pertaining to employees or modified the terms of any such existing contract or
agreement outside the Ordinary Course of Business; 

        f.      Company
has not granted any increase in the base compensation of any employees outside the Ordinary Course of Business; 

        g.     Company
has not adopted, amended, modified or terminated any Employee Benefit Plan; 

        h.     Company
has not made any other change in employment terms for any employees outside the Ordinary Course of Business; 

        i.      Company
has not made or committed to any capital expenditure other than in the Ordinary Course of Business; 

14

 

        j.      Company
has not entered into any binding agreement to do any of the foregoing; 

        k.     no
Contract or relationship with a supplier or customer has been terminated, and Company has not been informed that a supplier or customer intends to terminate a Contract
or relationship; and 

        l.      Company's
working capital has been reduced only in the Ordinary Course of Business. 

        24.    Inventory.    The raw materials and other items used by Company in the production and research and development
work of Company and Company's products are used in accordance with all applicable and necessary Laws, regulations and permissions and fulfill all the requirements of product safety regulations. There
are no claims pending against or, to the Knowledge of the Sellers, threatening Company concerning product liability, reclamation or guarantee. 

        25.    Technical Equipment.    The technical equipment and machines and the premises used by Company are, and at all
times while in operation by Company have been, in compliance with all safety regulations and requirements applicable thereto. Except as set forth on Disclosure Schedule III.A.25, no accidents
have occurred during the last three years due to any defaults in safety requirements. 

        26.    Product Warranty.    Disclosure Schedule III.A.26 lists (a) each product manufactured, sold,
leased or delivered by the Company that is subject to any Company guaranty, warranty, right of return or other indemnity, (b) each contract or agreement containing any such guaranty, warranty,
right of return or other indemnity and (c) the aggregate expenses incurred by the Company in fulfilling its obligations under such guaranty, warranty, right of return and indemnity provisions
during each of the fiscal years and the interim period covered by the Financial Statements. To the Knowledge of Sellers, there is no reason such expenses should significantly increase as a percentage
of sales in the future. 

        27.    Suppliers and Customers.    Disclosure Schedule III.A.27 sets forth a true and complete list of
(i) all suppliers that individually accounted for more than five percent (5%) of Company's aggregate purchases during the fiscal year ended December 31, 2005, and (ii) all
customers that individually accounted for more than three percent (3%) of the aggregate gross revenues during the fiscal year ended December 31, 2005, indicating the amount and percentage of
gross revenues for which each such customer was accountable. Except as listed on Disclosure Schedule III.A.27, no Person has notified Company in writing that it will cease doing business with
Company or will materially adversely change its business relationship with Company. 

        28.    Books and Records.    The corporate minute books and other similar records of Company contain true, accurate
and complete records of (i) all actions taken at any meetings of Company's managers, members or any committee thereof and of all written consents executed in lieu of the holding of any such
meeting and (ii) all Membership Interests issued and outstanding. 

        29.    Bank Accounts.    Disclosure Schedule III.A.29 lists all company bank accounts of Company by account
name, number, type, financial institution, name of the contact person at each such institution. Within two (2) business days after execution hereof, Sellers' shall provide Purchaser the balance
of each such account as of the date of this Agreement and within two (2) business days after Closing shall provide Purchaser the balance of each such account as of the Closing Date. 

        30.    Powers of Attorney.    Except as disclosed in Disclosure Schedule III.A.30, there are no outstanding
powers of attorney executed on behalf of the Company. 

15

 

        31.    Independent Tax and Business Advice.    Sellers have their own tax advisors and legal counsel and have not
relied on Purchaser or Purchaser's agents for financial, tax, or other business advice. 

        32.    Securities Matters.    

        a.    Securities Regulation.    Each Seller understands and acknowledges that the Purchaser Common Stock subject of
this Agreement has not been registered under the law of Canada or the United States Securities Act of 1933 or the securities laws of any state and is being offered and sold in reliance on exemptions
from the registration and qualifications of the Act and applicable state laws. The rights of all Parties to this Agreement are expressly conditioned upon the validity of such exemptions. Each Seller
further understands and acknowledges that (i) each Seller is being offered and would receive Purchaser Common Stock without being furnished any offering literature or prospectus,
(ii) this transaction has not been scrutinized by the United States Securities and Exchange Commission ("Commission") or by any administrative
agency charged with the administration of securities laws of
any state because of the small number of persons solicited and the private aspects of the offering, (iii) each Seller and each Seller's representatives (including each Seller's attorney and/or
accountant) has had access to publicly filed information regarding Purchaser. 

        b.    Accredited Investor.    Each Seller is an "Accredited Investor" under Regulation D of the United States
Securities and Exchange Commission. 

        c.    Age and Citizenship of Each Seller.    Each Seller is a citizen or permanent resident of the United States and
at least 21 years of age, a bona fide permanent resident of and is domiciled in the State of Texas and has no present intention of becoming a resident of any other state or jurisdiction. 

        d.    Purchase for Investment Purposes Only.    The Purchaser Common Stock is being purchased in good faith solely for
each Seller's own account and for investment purposes only. The Purchaser Common Stock is not being purchased for the account of any other person or with a view to or for sale in connection with any
distribution, assignment, subdivision, fractionalization, re-syndication or resale to others, and no other person has or will have a direct or indirect beneficial interest in the Purchaser
Common Stock. Each Seller has no contract or arrangement with any person or entity to sell, transfer or pledge to any person or entity the Purchaser Common Stock or any part thereof, any interest
therein or any rights thereto and has no present plans to enter into any such contract or arrangement. Each Seller understands and acknowledges that as a result each Seller must bear the economic risk
of investment for an indefinite period of time because the Purchaser Common Stock has not been registered, under the Act or otherwise (which Company is not obligated to do and has no present intention
of doing), unless an exemption from such registration is available. 

        33.    Schedules.    All Disclosure Schedules hereto are true, accurate and complete as of the date of this Agreement. 

        34.    Full Disclosure.    To Sellers' Knowledge, the statements made and information furnished by or on behalf of
Sellers or Company in this Agreement or in connection with the Contemplated Transactions do not contain any untrue statement of a material fact or omit to state any material fact necessary to make the
statements made or information furnished, taken as a whole and in light of the circumstances under which they were made or furnished, not false or misleading. 

16

 

        B.    Representations and Warranties of Purchaser.    Purchaser hereby represents and warrants to Sellers as follows: 

        1.    Organization and Qualification, etc.    Purchaser is duly organized, validly existing and in good standing under
the laws of its domicile and has full corporate and legal power and authority necessary to own, lease and operate its assets, to carry out its business as now conducted and to enter into this
Agreement and the Related Agreements to which it is a party and consummate the transactions contemplated hereby and thereby. 

        2.    Authority and Approval.    The execution, delivery and performance by Purchaser of this Agreement and the
Related Agreements to which it is to be a Party, and the consummation by Purchaser of the transactions contemplated in this Agreement and Related Agreements, have been duly authorized by all required
action on the part of Purchaser. This Agreement has been duly executed and delivered by Purchaser, and, when executed and delivered by Purchaser, the Related Agreements to which Purchaser is to be a
Party will have been duly executed and delivered by Purchaser. This Agreement is, and each of the Related Agreements to which Purchaser is to be a Party when executed and delivered by Purchaser will
be, the valid and binding obligations of each of Purchaser enforceable against Purchaser in accordance with their respective terms. 

        3.    No Conflict.    The execution and delivery by Purchaser of this Agreement and each of the Related Agreements to
which Purchaser is to be a Party, and Purchaser's compliance with the terms and conditions hereof and thereof, and the consummation by Purchaser of the transactions contemplated hereby and thereby, do
not and will not (i) require the consent of any Person under any material Contract to which Purchaser is a party, (ii) violate any provision of, or require any consent, authorization, or
approval under, any Law or Order applicable to it, (iii) violate, conflict with, result in a Breach of, constitute a default under (whether with or without notice or the lapse of time or both),
accelerate or permit the acceleration of the performance required by, or require any consent, authorization, or approval under, any material Contract or Permit to which Purchaser is a party or by
which Purchaser is bound or to which any of the Purchaser Common Stock is subject, or (iv) result in the creation of any Lien upon the Purchaser Common Stock. 

        4.    Governmental Approvals and Filing.    No consent, authorization, approval or action of, filing with, notice to,
or exemption from any Governmental or Regulatory Authority on the part of Purchaser is required in connection with the execution, delivery and performance of this Agreement or any Related Agreements
to which Purchaser is to be a party or to consummate the transactions contemplated hereby or thereby. 

        5.    Brokers.    Except for Stuart Barich of Oppenheimer & Co., Inc., who has been retained as
Purchaser's broker in connection with this Agreement and the Contemplated Transactions, no broker, finder or investment banker is entitled to any brokerage commission, finder's fee or similar payment
in connection with the transactions contemplated hereby based upon arrangements made by or on behalf of Purchaser. 

        6.    Litigation.    As of the date of this Agreement, there is no action, suit or Proceeding pending or, to the
Knowledge of Purchaser, threatened against Purchaser relating to the transactions contemplated by this Agreement or which, if adversely determined, would adversely affect the ability of Purchaser to
perform
its obligations and agreements under this Agreement and the Related Agreements to which it is or will be a party and to consummate the transactions contemplated herein and therein. 

        7.    Sufficient Funds.    Purchaser has and will have on the Closing Date sufficient cash or
cash-equivalent funds to consummate the transactions contemplated by this Agreement, including paying the cash portion of the Purchase Price. 

17

 

        8.    Public Filings; Financial Statements.    Purchaser is a reporting issuer in good standing under the securities
laws of the Province of Ontario and no material change relating to Purchaser or its Affiliates has occurred with respect to which a material change report has not been filed under any securities Laws
and no such disclosure has been made on a confidential basis. Purchaser has complied with the requirements of all applicable corporate Laws in relation to the issue and trading of its securities. The
Public Record complies with all securities Laws, is in all material respects accurate, contains no misrepresentations and omits no facts, the omission of which makes the Public Record or any
particulars therein, misleading or incorrect. "Public Record" means the annual and interim financial statements, management's discussion and analysis of
operating results, annual and quarterly reports to shareholders, management proxy circulars, prospectuses, annual information forms, material change reports and press releases and all other
information disseminated to the public or filed by Purchaser with any Canadian securities commission or exchange during the twelve (12) months preceding the date hereof. The issuance and sale
shares of Purchaser Common Stock hereunder are exempt from the registration and prospectus delivery requirements of all applicable securities Laws. Under applicable Canadian securities laws, the
Purchaser Common Stock issuable pursuant to Section I and listed on the TSX may be resold by the Sellers into Canada four (4) months after such payment without the filing of a prospectus
or any other document with any Governmental or Regulatory Authority. 

        9.    Valid Issuance of Stock.    The shares of Purchaser Common Stock issuable pursuant to Section I have been
duly created, allotted and reserved for issuance and, when issued and paid to the Sellers as provided in this Agreement, will be validly issued and outstanding as fully paid and non assessable shares
of Purchaser. The Purchaser Common Stock is listed and posted for trading on the TSX. 

IV.    COVENANTS  

        A.    Appointment.    Provided Williams fulfills all criteria imposed by law and the TSX to act as director in a
Federal Canadian Business Corporation, then on or prior to Closing Purchaser shall cause its Board of
Directors to appoint Williams to its Board of Directors and shall add Williams to the slate of Directors in Purchaser's proxy material for reelection at the next annual meeting of Purchaser's
shareholders. 

        B.    Waiver of First Refusal Rights.    Each Seller hereby waives all rights of first refusal that such Seller may
have under Section 2.04 of the Regulations of Company. 

        C.    Publicity.    Sellers and Purchaser shall not, and shall cause their agents and Affiliates not to, publish,
engage in, encourage or support any publicity or disclosure of any kind or form of the transactions contemplated herein, the existence of a transaction between the Parties or the terms of this
Agreement or any Related Agreements, without obtaining the prior written approval of the other Party, unless disclosure is otherwise required by applicable law. The clause above shall not prevent
Purchaser from disclosing necessary information, including this Agreement, to possible future investors in Company or Purchaser. 

        D.    Diligence.    Following the execution hereof until Closing, Sellers shall continue to provide Purchaser and its
agents with reasonable access during regular business hours to all of the Company's books, records, property, employees and agents for Purchaser's purposes of investigating and conducting due
diligence regarding the Company's assets, liabilities and business operations, and until the Closing Date Seller shall cause the Company and its employees and agents to cooperate fully with Purchaser
in its investigations, provided, however, that Purchaser shall not contact any employees of the Company
(other than Sellers) without the prior approval of Williams. In connection with Purchaser's due diligence, Purchaser shall have the right but not the obligation to conduct a full audit or review of
the Company since its inception by a certified public accounting firm selected by Purchaser and reasonably acceptable to Seller, and Seller shall cause all of the Company's employees and agents to
cooperate fully in connection with such audit. The cost of any such audit shall be paid by Purchaser. 

18

   
        E.    Non-Competition    

        1.    Covenant Not to Compete.    For a period of five (5) years from the date of Closing, each of Koleng,
Zhang and Crowley shall not, directly or indirectly, individually or as an officer, director, manager, employee, shareholder, consultant, contractor, partner, member, joint venturer, agent, equity
owner or in any capacity whatsoever (and Williams and McGinity shall not directly or individually): 

        a.     own,
engage in, manage, operate, join, control, be employed by, provide Competing Services to, or participate in the ownership, management, operation or control of or
provision of Competing Services to, a Competing Business operating in the Geographic Area; 

        b.     recruit,
hire, assist in hiring, attempt to hire, or contact or solicit with respect to hiring any person who, within the prior six month period, was an employee of the
Company; 

        c.     induce
or attempt to induce any person who, within the prior 12 month period, was an employee of the Company, to terminate, or in any way interfere with, the
relationship between such person and the Company; or 

        d.     induce
or attempt to induce any customer, client, supplier, service provider, or other business relation of the Company or its Affiliate in the Geographic Area to cease
doing business with the Company or its Affiliate, or in any way interfere with the relationship between the Company or its Affiliate and any such person. 

        2.     Notwithstanding
the provisions above, Purchaser and the Company agrees that each Seller may own not more than two percent (2%) of the outstanding voting securities of any
publicly traded company that is a Competing Business. 

        3.     Notwithstanding
the provisions above, this Section IV.E shall not prevent or hinder McGinity or Williams from continuing to engage in teaching, publishing,
lecturing, consulting or other activities in which they were engaged on the Closing Date, specifically including the activities set forth on  Exhibit IV.E.3. Any other activities in which McGinity
or Williams desire to engage after Closing, and
that may violate this Section IV.E, shall require prior written consent of the Company's Board of Managers, such consent not to be unreasonably withheld. 

        4.    Definitions.    

        a.     "Competing Business" means any commercial business that (i) provides, as its primary business, research,
development, formulation, testing or manufacturing services for non-parenteral pharmaceutical products, (ii) provides, as its primary business, the research, development,
formulation, testing or manufacturing of a platform for pulmonary or transmucosal application or abuse deterrent formulation of drugs, or (iii) develops a patented anti-asthmatic
drug or product related to human growth hormone that competes with a company drug or product. 

        b.     "Competing Services" means services that, if provided to a business other than a Competing Business, would constitute the
conduct of a Competing Business. 

        c.     "Geographic Area" means North America, Europe, Japan and Australia. 

        5.    Specific Performance; Equitable Relief.    Sellers acknowledge and agree that any Breach of this
Section IV.E is likely to result in irreparable injury to Company and Purchaser, that monetary damages will be an inadequate remedy of such Breach and that, accordingly, in addition to any
other remedy that Purchaser may have, Purchaser shall be entitled to enforce the specific performance of this Section IV.E and to seek both permanent and temporary relief in the event of any
Breach or threatened Breach thereof without the necessity of posting bond or proving that there is no adequate remedy at law or imminent irreparable harm to Purchaser. Sellers agree that 

19

 

in
addition to any and all other remedies available to Purchaser, an injunction or restraining order or other equitable relief may be issued or ordered by a court of competent jurisdiction restraining
any Breach or threatened Breach of this Section IV.E. 

        6.    Conditions Reasonable.    Sellers acknowledge and agree that the time, scope, geographic area and other
provisions of this Section IV.E have been specifically negotiated by sophisticated commercial Parties with benefit of legal counsel and agree that all such provisions are reasonable under the
circumstances. If any portion of this Section IV.E shall be determined to be invalid and unenforceable as written, each such portion shall be enforced to the extent reasonable under the
circumstances and such determination shall not affect the validity or enforceability of the other provisions of this Agreement, and such other provisions shall remain in full force and effect. Sellers
understand and acknowledge that they are agreeing to be bound by these non-competition provisions in order to induce Purchaser to enter into this Agreement. 

        7.    Covenants in Employment Agreements.    Expiration of the five (5) year non-competition term
provided above shall have no effect on the enforceability of any non-competition provision contained in any Employment Agreement or Consulting Agreement. 

        F.    Investigation and Agreement by Purchaser; No Other Representations or Warranties.    

        1.     Purchaser
acknowledges and agrees that it has made its own inquiry and investigation into, and, based thereon, has formed an independent judgment concerning, the Company
and the Business, and Purchaser has been furnished with or given full access to such information about the Company and the Business as it requested. In connection with Purchaser's investigation of the
Company and the Business, Purchaser and its representatives have received from the Company, the Sellers or their representatives certain projections and other forecasts for the Company and certain
estimates, plans and budget information. Purchaser acknowledges and agrees that (a) there are uncertainties inherent in attempting to make such projections, forecasts, estimates, plans and
budgets; (b) Purchaser is familiar with such uncertainties; and (c) Purchaser is taking full responsibility for making its own evaluations of the adequacy and accuracy of all estimates,
projections, forecasts, plans and budgets so furnished to it or its representatives. 

        2.     Purchaser
agrees that, except for the representations and warranties made by the Sellers that are expressly set forth in Section III.A of this Agreement, none of
the Company, any Seller, or any of their respective Affiliates or representatives has made and shall not be deemed to have made to Purchaser or its respective Affiliates or representatives any
representation or warranty of any kind. 

        G.    Waiver.    Purchaser each hereby waives, and agrees to cause the Company to waive, any conflicts that may arise
in connection with (a) Vinson & Elkins L.L.P., counsel to the Company, representing the Sellers following the Closing and (b) the communication by such counsel to the Sellers, in
connection with any such representation, any fact known to such counsel, including in connection with a dispute with Purchaser or the Company on or following the Closing. 

        H.    Operating Covenants.    Purchaser agrees to act in good faith and use commercially reasonable efforts to:
(i) promote and support the Business, (ii) achieve the Phase I Triggering Event, Phase II Triggering Event and Phase III Triggering Event, (iii) not change
its Company's line of Business, (iv) manage and run Company's Business in a manner at least as likely to achieve the Phase I Triggering Event, Phase II Triggering Event and
Phase III Triggering Event as the past practices of the Company, and (v) provide capital, assets, facilities and support to the Company substantially in accordance with the budgets for
the Company previously provided to Purchaser. Notwithstanding the foregoing sentence, neither the sale of the Company by Purchaser nor the sale by Company of substantially all of its assets shall
constitute a breach by Purchaser of this Section IV.H; provided, that effective immediately upon any such sale each of the Phase I
Triggering Event, the Phase II Triggering 

20

 

Event
and the Phase III Triggering Event shall be deemed to have been achieved and met (to the extent not otherwise achieved prior to such date) for all purposes of this Agreement,
notwithstanding the definitions thereof set forth in Section I.D (but subject to Section I.D.4). 

        I.    Notice.    The Sellers shall give prompt notice to Purchaser upon becoming aware of: 

        1.     any
notice or communication to the Company from any Person alleging that the consent of such Person is required in connection with the Closing; 

        2.     any
fact or condition that either (i) occurred prior to the date hereof and constitutes a misrepresentation or breach of any of the representations or warranties
made by the Sellers as of the date hereof or (ii) occurred on or after the date hereof and would constitute such a misrepresentation or breach if such fact or condition had occurred prior to
the date hereof; 

        3.     any
Material Adverse Effect; or 

        4.     the
failure of the Sellers to satisfy in any material respect a covenant required to be complied with by them hereunder. 

        J.    Existing Guaranties.    Purchaser understands that McGinity and Williams have executed personal guaranties with
regard to the Leases and with regard to certain financial obligations of Company. Purchaser agrees to use commercially reasonable efforts to have McGinity and Williams released from all such personal
guaranties and, in the event such releases cannot be obtained, to indemnify McGinity and Williams from loss under such guaranties. 

        K.    SIMPLE-IRA Indemnity.    Sellers shall indemnify, defend and hold harmless Purchaser and Company for
any and all costs and expenses that either actually incurs (including without limitation all reasonable attorneys' fees and all fees and penalties, if any, assessed by the Internal Revenue Service) as
a result of or arising out of any errors associated with the operation of the Formulation Technologies, L.L.C. SIMPLE-IRA Plan; provided,  however, any
indemnification arising pursuant to this Section IV.K must be the result of an Internal Revenue Service audit or a participant
initiated inquiry which, in each case, is not the result of any Purchaser or Company initiated action primarily related to the Formulation Technologies, L.L.C. SIMPLE-IRA Plan after the
date hereof. If any Internal Revenue Service action or participant claim arises pertaining to the Formulation Technologies, L.L.C. Simple-IRA Plan, the Sellers shall have full authority to
control the defense of any such action and choose the attorneys or other service providers to assist in the defense and shall have complete authority to concede to any settlement or litigate any
action. Notwithstanding the foregoing, the Sellers shall remain liable for any additional costs or expenses that may arise from their defense of any applicable action. The provisions of this
Section IV.K shall not be subject to the provisions of Section V.C below and shall survive Closing Date for the applicable statute of limitations. 

        L.    License Agreement Interpretation.    Each Seller agrees that (a) Company's intent with respect to
Section 2.4 of the License Agreement, dated as of January 26, 2005, between Company and Auxilium Pharmaceuticals, Inc. (the "License Agreement") at the time such License Agreement
was entered into was that the restriction contained therein applied only to Combination Products (as defined in the License Agreement) related to Therapeutic Areas under Licensor Technology and
Licensor Know-How (each as defined in the License Agreement), (b) the Business has been operated in accordance with such intent at all times from and after the date of the License
Agreement, and (c) such Seller shall take such actions as may be reasonably necessary or desirable to effect the interpretation and enforcement of the License Agreement in accordance with the
Company's intent set forth above. 

21

 

V.     INDEMNIFICATION  

        A.    Indemnification by Sellers:    

        1.     Subject
to the terms and conditions of this Agreement, if the Closing occurs, Sellers, severally (but not jointly) will indemnify and hold harmless Purchaser against and
in respect of any Damages suffered or incurred by Purchaser resulting from any of the following: 

        a.     any
Breach of any representation or warranty of Sellers in this Agreement or any Assignment of Membership Interests; 

        b.     any
Breach by Sellers of any of their covenants or agreements in this Agreement or any Assignment of Membership Interests; 

        c.     Any
noncompliance with fraudulent transfer Laws by Sellers in the sale of the Membership Interests to Purchaser where an element of the claim resulting in the Damages is
either that a Seller was not Solvent at the date the transfer of the Membership Interests was made under this Agreement or such transfer was made with actual intent of Sellers to hinder, delay or
defraud any entity to which Sellers were or become indebted; provided, however, nothing in this
provision is intended to imply that Sellers are not Solvent or that Sellers have any intent to hinder, delay or defraud creditors. 

        B.    Indemnification Procedures.    

        1.     If
a claim for Damages (an "Indemnification Claim") is proposed to be made by Purchaser against Sellers, Purchaser will
give notice (an "Indemnification Claim Notice") to Sellers as soon as practicable after Purchaser becomes aware of any fact, condition or event which
may give rise to Damages for which indemnification may be sought under this Article V. The failure of Purchaser to give timely notice of a Claim pursuant to this Section V.B.1 will not
affect the rights of Purchaser or the obligation of Sellers under this Article V, except to the extent that the resulting delay prejudices the position of the Seller(s). An Indemnification
Claim Notice will describe in reasonable detail the nature of the Indemnification Claim, including an estimate of the amount of Damages that have been or may be suffered or incurred by Purchaser
attributable to such claim (to the extent reasonably ascertainable at such time), and the basis of Purchaser's request for indemnification under this Agreement. Further, Purchaser will cooperate with
Sellers and will provide to Sellers such information in Purchaser's possession that relates to such claim. 

        2.     If
any third party makes any claim (a "Third Party Claim") or commences any action or proceeding (a
"Third Party Action") with respect to any matter as to which a Purchaser intends to seek indemnification under this Article V, Purchaser shall
promptly give notice (a "Third Party Claim Notice") to Sellers of the existence of the Third Party Claim or the commencement of the Third Party Action
(and in any event within ten Business Days after the service of any summons or citation). The failure of Purchaser to give timely notice hereunder will not affect rights to indemnification hereunder,
except to the extent that the resulting delay prejudices the position of the Seller(s). A Third Party Claim Notice will describe in reasonable detail the nature of the Third Party Claim and Third
Party Action, including an estimate of the amount of Damages that have been or may be suffered or incurred by Purchaser attributable to such claim (to the extent reasonably ascertainable at such
time), the basis of Purchaser's request for indemnification under this Agreement and all information in Purchaser's possession relating to such claim. 

        3.     Sellers
will be entitled at any time to participate in the defense of any Third Party Claim or Third Party Action with counsel of its own choice. The Parties agree to
cooperate fully with one another in connection with the defense and/or settlement of the claim or action. Additionally, Sellers will have the right at any time to substitute counsel and, upon
substitution of counsel, to undertake and direct the defense of such claim or action, provided, that the substitution of counsel 

22

 

does
not materially impair the defense of the claim or action. Sellers may exercise their right to undertake and direct the defense of a claim or action by giving notice to Purchaser in the manner
provided in this Agreement. After Sellers undertake the defense of a claim or action, Purchaser may participate in the defense at its own expense. If Sellers fail to conduct actively and diligently a
defense of a claim or action undertaken by Sellers, then Purchaser may undertake and direct the defense by giving notice to Sellers in the manner provided in this Agreement and the expense of such
defense shall be recoverable as Damages to the extent that Sellers are obligated under this Article V to indemnify Purchaser for the Third Party Action. 

        4.     If
Sellers fail to undertake the defense of any Third Party Action within twenty (20) days after receipt of the Third Party Claim Notice as to such action,
Purchaser may undertake the defense of such action at Sellers' expense if and to the extent Sellers are obligated under this Article V to indemnify Purchaser for the Third Party Action. In that
case, (i) Sellers will no longer have the right to direct such defense or the Third Party Action (unless Sellers shall later elect to undertake the defense), (ii) Purchaser will conduct
the defense of the Third Party Action actively and diligently, and (iii) Sellers will cooperate with Purchaser in such defense and make available to Purchaser, at Sellers' expense, all such
witnesses, records, materials and information in Sellers' possession or under Sellers' control relating thereto as is reasonably requested by Purchaser. 

        5.     Any
Party conducting the defense of a Third Party Claim or Third Party Action will keep the other Party advised as to its current status and progress. Purchaser will not
make any offer of settlement with respect to any such claim or action if Sellers have undertaken the defense of the claim or action. If Sellers have not undertaken the defense of such claim or action,
Purchaser agrees not to make any offer of settlement with respect to such claim or action without first having provided fifteen (15) days' advance written notice to Sellers and having obtained
the written approval of Sellers, which approval will not be unreasonably delayed or withheld. In the event Sellers undertake the defense of any such claim or action, Purchaser will nevertheless be
entitled to participate in (but not direct) the defense of the claim or action with counsel of its own choice, and the Parties agree to cooperate fully with one another in connection with the defense
and/or settlement thereof; provided, however, that any settlement or compromise of any such claim or
action that does not include the release of Purchaser from all related liability shall require the written approval of Purchaser, which consent will not be unreasonably withheld or delayed. From and
after the date that Sellers assume the defense of any such claim or action, Sellers will be relieved of the obligation to reimburse Purchaser for any other legal, accounting, or other
out-of-pocket costs and expenses thereafter incurred by Purchaser with respect to the defense of such claim or action notwithstanding any participation by Purchaser therein. 

        6.     The
obligation of Sellers to indemnify Purchaser for any reason whatsoever shall terminate four (4) years after the Closing Date, after which date Sellers shall
have no further liability in respect of the transactions contemplated hereunder, including for fraud and Breach of representations and warranties under the following Sections: 

            i.  Section III.A.3
(Capital Structure) 

           ii.  Section III.A.21
(Environmental Matters) 

          iii.  Section III.A.22
(Payment of Taxes; Tax Liens) 

        7.     In
the event no agreement regarding any Indemnification Claim shall have been made within sixty (60) days from Sellers' receipt of the Indemnification Claim,
Purchaser shall have the right to initiate arbitration proceedings in accordance with Article VII (Dispute Resolution). 

23

 

        C.    Limitation of Sellers' Liability    

        1.     Sellers'
liability for Breach of any representation or warranty contained in this Agreement shall be limited as follows: 

        a.     Sellers'
indemnification obligations under this Agreement shall be several and not joint and shall be pro rata to each Seller's Percentage Interest in the Company
immediately prior to the consummation of the transactions contemplated herein; provided, that a Seller shall be solely liable for (and no other Seller
shall have indemnification obligations with respect to) (i) any indemnification obligation arising from or relating to such Seller's Breach of any Related Agreement to which such Seller is a
party or otherwise related to such Seller's obligations thereunder and (ii) any Breach of this Agreement by such Seller with respect to provisions applying to such Seller (e.g. a Breach of a
representation or warranty regarding the authority of such Seller). 

        b.     Sellers
shall be obligated to indemnify Purchaser only if Damages exceed the total of $125,000 and only for Damages in excess of (but not including) such amount (the
"Deductible") and then only up to an aggregate of $3,750,000 of Damages (the "Cap"),  provided, the
Deductible and the Cap shall not
apply to Damages arising from (i) fraud or (ii) from Breach of representations and warranties under the following Sections (the "Excluded Representations and
Warranties": 

            i.  Section III.A.3
(Capital Structure) 

           ii.  Section III.A.21
(Environmental Matters) 

          iii.  Section III.A.22
(Payment of Taxes; Tax Liens) 

        c.     The
Cap shall be reduced over time as follows: 

            i.  to
$2,500,000 six months after the Closing Date; 

           ii.  to
$1,250,000 one year after the Closing Date; and 

          iii.  to
$0 eighteen months after the Closing Date. 

        Notwithstanding
the foregoing, if Purchaser has previously delivered to Sellers an Indemnification Claim and such claim has not been fully resolved in accordance with the provisions of
this Agreement at the time of the Cap reductions contemplated above, then, solely with respect to such unresolved Indemnification Claim, the Cap shall be reduced to an amount equal to the applicable
amount shown above plus the amount of any then-existing unresolved Indemnification Claim until the time such Indemnification Claim is resolved. 

        2.     For
the purposes of this Agreement, a Liability that is a contingent liability shall not constitute Damages, unless and until such contingent liability becomes an actual
liability and is due and payable. 

        3.     Except
with regard to Damages resulting from fraud or breach of Section III.A.3 (Capital Structure), Purchaser's sole source of recovery for a claim for
indemnification under this Article V is by offsetting against remaining payments of the Purchase Price. 

        4.     If
any Liability that otherwise would be considered Damages is a tax deductible item, or relates to an untaxed reserve, the Indemnification Claim that Purchaser may make
shall be reduced by an amount equivalent to the deficiency, cost or loss multiplied by the corporate tax rate applicable in the jurisdiction of the Company or Purchaser, as the case may be, at the
time of the reimbursement. 

24

 

        5.     Purchaser
shall not be entitled to make any Indemnification Claim to the extent that a provision or allowance for the matter of the deficiency, cost or loss (whether as a
specific reserve or as a general reserve) has been made in the Interim Balance Sheet, or the same is otherwise accounted for or reflected in the Interim Balance Sheet. 

        6.     No
Damages shall arise in respect of any Breach of this Agreement or otherwise: 

        a.     if
and to the extent that any Indemnification Claim occurs as a result of any legislation not in force on the date hereof, or which takes effect retrospectively, or
occurs as a result of any increase in the rate of tax in force at the date hereof or any change in the practice of the relevant tax authorities; nor 

        b.     if
Damages would not have arisen but for an act, omission or transaction of whatever nature carried out by Purchaser or Company, or persons deriving title from Purchaser
or Company, after Closing. 

        7.     No
Damages shall arise in relation to any Breach in respect of any deficiency, cost or loss, which (A) is recoverable under a policy of insurance in force on the
Closing Date, (B) is recoverable under any other policy of insurance in force after the Closing Date, (C) would have been recoverable had the insurance protection level, which existed on
the Closing Date, been continued, (D) has been recovered by any indemnification or compensation (on whatever basis) from any third party. 

        8.     If
a failure by Sellers to perform their obligations under this Agreement is capable of being remedied, Purchaser shall not be entitled to Damages for any Breach unless
Sellers are given written notice of such failure and either (i) fail to commence remedial action within thirty (30) days of such notice; (ii) fail to pursue such action diligently
at all times thereafter until the original failure has been remedied; or (iii) fail to remedy the original failure within ninety (90) days after such notice. 

        9.     For
the avoidance of doubt, it is understood and agreed that to the extent that an Indemnification Claim has been satisfied under a provision of this Agreement, no claim
for such Damages may be made under any other provision of this Agreement. 

        10.   Purchaser
and its Affiliates each acknowledges and agrees that, from and after the Closing, notwithstanding any other provision of this Agreement to the contrary, the
sole and exclusive remedy of the Purchaser with respect to claims for Damages or otherwise, in connection with, arising out of or resulting from the subject matter of this Agreement and the Related
Agreements and the transactions contemplated hereby and thereby, shall be in accordance with, and limited solely to indemnification under, the provisions of this Article V. 

        11.   No
Seller shall be liable for any Damages that are indemnifiable hereunder unless a written Indemnification Claim is delivered by the Purchaser to the Sellers prior to
the applicable Expiration Date. 

        12.   In
connection with any Indemnification Claim, Purchaser and its Affiliates shall use commercially reasonable efforts to seek and pursue any available insurance coverage
or other claims against third parties that such Person may have in respect of the Damages, and if such Person receives any such amounts subsequent to an indemnification payment by the Sellers in
respect of such Damages, then such Person shall promptly reimburse the Sellers for any payment made or expense incurred by the Sellers in connection with providing such indemnification payment up to
the above amounts so received by such Person. 

25

  

        13.   For
all Tax purposes, the Parties agree to treat (and shall cause each of their respective Affiliates to treat) any indemnity payment under this Agreement as an
adjustment to the Purchase Price unless a final and nonappealable determination by an appropriate Governmental or Regulatory Authority (which shall include the execution of an IRS
Form 870-AD or successor form) provides otherwise; provided, that the Sellers prior written consent (which will not be unreasonably
withheld or delayed) will be obtained by the Purchaser and its Affiliates who seeks to accept, via a settlement or compromise with any such Governmental or Regulatory Authority, a position that is
contrary to treatment of an indemnity payment as an adjustment to the Purchase Price. 

        14.   If
the Closing occurs, Purchaser shall be deemed to have waived all Breaches of representations, warranties and covenants of the Sellers of which Purchaser has
Knowledge, and the Sellers shall have no liability with respect thereto after the Closing. For purposes of this subsection V.C, the term "Knowledge" shall mean only the actual knowledge on the
Closing Date of Halvor Jeager, Dr. Günter Knorr or Andrew Reiter. 

VI.   TERMINATION  

        A.    Termination.    This Agreement may be terminated at any time prior to the Closing: 

        1.     by
the mutual written consent of Sellers and Purchaser; 

        2.     by
either Sellers or Purchaser if there shall have been any breach by the other Party of any representation, warranty, covenant or agreement set forth in this Agreement,
which breach (a) would give rise to the failure of a condition to the Closing hereunder and (b) either (i) cannot be cured or (ii) if it can be cured, has not been cured
prior to 5:00 p.m. on the date that is twenty (20) days following receipt by the breaching party of written notice of such breach; 

        3.     by
either Sellers or Purchaser if there is an order or decree restraining, enjoining, prohibiting, invalidating or otherwise preventing to a material degree the
consummation of the Contemplated Transactions; or 

        4.     by
either Sellers or Purchaser, if the Closing shall not have occurred within ninety (90) days of execution hereof,  provided, however, that the right to
terminate this Agreement under this Section VI.A.3 shall not
be available to any Party whose failure to fulfill any obligation under this Agreement shall have been the cause of, or shall have resulted in, the failure of the Closing to occur on or prior to such
date. 

        B.    Effect of Termination.    In the event of termination of this Agreement as provided in Section VI.A
above, this Agreement shall forthwith become void and there shall be no Liability on the part of any Party hereto, except that the obligations of the Parties set forth in Section IV.C
(Publicity), Article VII (Dispute Resolution), VIII.A (Expenses, Brokers' and Finders' Fees), VIII.C (Set-Off), VIII.D (Governing Law), VIII.F (Notices),
VIII.J (Confidentiality) and VIII.K (Interpretation) hereof shall survive any such termination and shall be enforceable hereunder, and except that nothing herein shall relieve any Party
from Liability for any willful Breach of any other provision hereof. 

        C.    Confidentiality.    Sellers have and will disclose to Purchaser information regarding the Business. If this
Agreement is terminated as provided in Section VI.A, then Purchaser shall, within thirty (30) days of such termination, return to Seller all Confidential Information, as well as any
copies thereof. Further, Purchaser shall within such thirty (30) day period destroy or return to Seller all summaries, compilations or similar documents that Purchaser may have derived from
such material. 

26

 

VII. DISPUTE RESOLUTION  

        A.    Dispute Resolution.    

        1.    Disputes.    Except as otherwise provided in this Agreement, any dispute, controversy or claim, counterclaim, or
cross claim, whether based on contract, tort, statute, fraud, misrepresentation or any other legal theory between Sellers, on the one hand, and Purchaser on the other hand (a
"Dispute"), that arises out of or relates to this Agreement or any obligations or related services to be provided
hereunder shall be resolved in accordance with the procedures described in this Article VII. Without limiting the generality of the foregoing, the matters subject to this Article VII
shall include the following: (i) any claim of Breach of this Agreement or for an Indemnification Claim, (ii) any question regarding the existence, validity or termination of this
Agreement, (iii) any claim that this Agreement or any portion of this Agreement is invalid, illegal or otherwise voidable, (iv) any dispute or claim as to whether a matter is arbitrable
under this provision, (v) any and all claims and rights arising under local, state or federal laws, statutes, ordinances or regulations, (vi) any dispute concerning the power and
authority to decide if a class action is authorized, (vi) any dispute or claim in a class action; and (vii) any dispute or claim resulting or growing out of activities performed or
obligations imposed under this Agreement, regardless of whether the dispute or claim sounds in contract, tort, strict liability or a statutory cause of action. 

        2.    Internal Dispute Resolution.    In the case of a Dispute, the Parties shall establish an internal hierarchy to
facilitate resolution of any Dispute as set forth below: 

        a.     Upon
written request of Sellers or Purchaser, each of Sellers and Purchaser shall appoint a designated representative whose task shall be to meet for the purpose of
resolving such Dispute. Prior to any initial meeting, the designated representative shall provide to each Party written notice of any Dispute, which notice shall include a detailed description of the
Dispute sufficient to allow a full analysis and complete response. Each Party shall exercise good faith in providing its response to any Dispute, in advance of the first meeting between or among
designated representatives. The designated representatives shall meet as often as the Parties reasonably deem necessary to discuss the Dispute in an effort to resolve the Dispute without the necessity
of any further proceeding. 

        b.     Each
of Sellers and Purchaser shall negotiate in good faith in an attempt to resolve the Dispute for a period of not greater than sixty (60) days after notice of
the Dispute is received by the Parties. 

        c.     If
the Parties are unable to resolve any Dispute as contemplated by this Section VII.A.2, the dispute shall be submitted to mandatory and binding arbitration at
the election of either Sellers or Purchaser for itself and its Affiliates. 

        B.    Mandatory Arbitration.    

        1.     The
arbitration proceeding shall be conducted by three (3) arbitrators under the Commercial Arbitration Rules of the American Arbitration Association in effect at
the time demand for arbitration is made, and under the Federal Arbitration Act in effect at the time demand for arbitration is made. The Parties may agree to use one (1) arbitrator under
Section VII.B.6, when applicable. Judgment on the award of the arbitrators may be entered by any court of competent jurisdiction. 

        2.     The
arbitration shall take place in the City of Austin, Travis County, Texas, and the proceeding shall be conducted in the English language. 

        3.     The
governing law for the arbitration shall be the law of the State of Texas. 

27

 

        4.     An
award of the arbitrators shall be exclusive, final and binding on all Parties, their successors and assigns and subject to judicial review only under the limited
circumstances described in the Federal Arbitration Act. 

        5.     The
litigation of any issues relating to vacating, modifying, or correcting the award or claims about the arbitrator or the arbitration shall be brought in the courts in
Travis County, Texas. 

        6.     Notwithstanding
any other provision of this Agreement, if the claim submitted to arbitration is for actual damages of $100,000 or less, then a single arbitrator shall
decide the matter and all other provisions hereof shall be construed in a manner consistent with the use of one arbitrator. 

        7.     No
Special Damages may be awarded by the arbitrator(s). Any other remedy allowed by applicable law shall be available, including temporary relief while matter is pending
in arbitration. 

        8.     Failure
to demand arbitration within four years of the date that a Party actually knows of the facts upon which a claim is based shall be a waiver of the claim and of the
right to submit the claim to arbitration. Whether a claim and the right to arbitrate the claim have been waived may be determined by arbitration. For clarification, the foregoing in no way extends the
survival period(s) in Section VIII.M below. 

        9.     The
arbitrators shall make an award within ninety (90) days of the date the receipt of evidence by the arbitrators is closed. 

        10.   Any
Party may invoke arbitration by demanding arbitration in a notice to the other Party and any required submission of the matter to the American Arbitration
Association. 

        11.   The
arbitrators shall permit discovery and rule on matters of confidentiality as they determine is appropriate under the circumstances. 

        12.   If
a Party desires to have a transcript of the arbitration proceeding, that Party must give notice to the arbitrators and to the other Party not less than ten
(10) days before the hearing (counting back from the date of the hearing commences). If both Parties give notice, then the Parties shall arrange for one reporter and split equally the cost of
the reporter and one copy of the transcript for each Party and one original and two copies for the arbitrators (unless there is only one arbitrator, in which case the cost of one original for the
arbitrator). 

        C.    Extraordinary Relief.    Notwithstanding these arbitration provisions, the Parties may seek extraordinary relief
in a court of competent jurisdiction to enforce this Agreement or any provision thereof or to maintain the status quo pending dispute resolution or as otherwise permitted by the terms of this
Agreement. 

VIII. MISCELLANEOUS  

        A.    Expenses, Brokers' and Finders' Fees.    Sellers and Purchaser shall each bear their own expenses incurred in
connection with the negotiation and execution of the Agreement. Each Party will indemnify and hold the other Party harmless from any claim for brokers' or finders' fees arising out of the transactions
contemplated hereby by any person claiming to have been engaged by such Party. 

        B.    Further Assurances.    Sellers and Purchaser each agree to execute and deliver such other documents or
agreements and to take such other action as may be reasonably necessary or desirable for the implementation of this Agreement and the consummation of the transactions contemplated herein. Each Party
shall, and shall cause each of their respective Affiliates to execute and deliver such additional instruments, documents, conveyances or assurances and take such other actions as shall be necessary,
or otherwise reasonably be requested by the other Party, to confirm and assure the rights 

28

 

and
obligations provided for in the Agreement and render effective the consummation of the transactions or otherwise to carry out the intent and purposes of this Agreement. 

        C.    Set-Off.    Except as otherwise specifically provided in this Agreement, any amount payable by one
Party to the other Party under the Agreement that is not disputed by the other Party or is the result of an arbitration proceeding in accordance with the provisions of this Agreement may be set off
against any amount owed to such Party by such other Party under the Agreement or otherwise that itself is not disputed by the other Party or is the result of an arbitral or juridical process. 

        D.    Governing Law.    This Agreement and any related issues shall be governed by and construed in accordance with
the laws of Texas, without regard to its conflicts of laws principals. 

        E.    Modifications, Waivers, Entire Agreement.    

        1.     No
amendment, modification or discharge of this Agreement, including changes to this Section VIII.E, shall be valid or binding unless made in writing. Statements
shall constitute a waiver only with respect to the specific matter described in such writing and shall in no way impair the rights of the Party granting such waiver in any other respect or at any
other time. 

        2.     Failure
by any Party at any time or times to require performance of any provisions of this Agreement shall in no manner affect its right to enforce the same, and the
waiver by any Party of any Breach of any provision of this Agreement shall not be construed to be a waiver by such Party of any succeeding Breach of such provision or waiver by such Party of any
Breach of any other provision hereof. 

        3.     This
Agreement, including the exhibits and schedules hereto and the other certificates, documents and instruments delivered hereunder, the Related Agreements and the
Confidentiality Agreement constitute the entire agreement of the Parties hereto and supersede all prior agreements, letters of intent and understandings, both written and oral, among the Parties with
respect to the subject matter of this Agreement, the Related Agreements and the Confidentiality Agreement. There are no representations or warranties, agreements or covenants other than those
expressly set forth in this Agreement, the Related Agreements and the Confidentiality Agreement. 

        F.    Notices.    All notices and other communications under this Agreement shall be in writing and shall be deemed
given when (i) delivered personally, (ii) mailed by certified mail, return receipt requested, or (iii) sent for overnight delivery by courier to the Parties (and shall also be
transmitted by facsimile to the Persons receiving copies thereof) to the Parties at the addresses set forth below (or to such other address as a Party may have specified by notice given to the other
Party pursuant to this provision), provided, that service of process under this Agreement may only be delivered by personal delivery: 

        If
to Sellers, to: 

Robert
O. Williams III

4514 West Rapid Springs Cove

Austin, Texas 78746

Telephone: 512.306.8396

Facsimile: 512.306.8396 

Michael
Crowley

13305 Council Bluff Drive

Austin, Texas 78727

Telephone: 512.834.0449 (x202)

Facsimile: 512.834.2105 

29

 

Feng
Zhang

17133 Bishopsgate Drive

Pflugerville, Texas 78660

Telephone: 512.252.3686

Facsimile: 512.252.3686 

John
J. Koleng

11113 Alison Parke Trail

Austin, Texas 78750

Telephone: 512.401.0280

Facsimile: 512.401.0280 

Daniel
J. Bates, Sr.

4614 Bunny Run

Austin, TX 78746-1011

Telephone: 512.327.5579

Facsimile: 512.329.8751 

James
W. McGinity

4209 Dunning Lane

Austin, Texas 78746

Telephone: 512.565.6921

Facsimile: 512.471.4843 (prior phone call required) 

with
a copy to: 

Kyle
K. Fox

Vinson & Elkins L.L.P.

The Terrace 7

2801 Via Fortuna, Suite 100

Austin, Texas 78746

Telephone: (512) 542-8539

Facsimile: (512) 236-3340 

If
to Purchaser, to: 

LAB
International Inc.

at 333 Cote Vestu,

Montreal, Canada H4R 2N1

Attention: Halvor Jaeger, President and CEO

Telephone: +1 (514) 315-3330 X 104

Facsimile: +1 (514) 315-3325 

with
a copy to: 

Terry
McDonald

McGinnis, Lochridge & Kilgore, LLP

600 Congress Avenue, Suite 2100

Austin, Texas 78701

Telephone: (512) 495-6019

Facsimile: (512) 505-6319 

        G.    Severability.    If any provision of this Agreement is held to be invalid or unenforceable for any reason, the
validity and the enforceability of the remainder of this Agreement shall not be affected. The Parties shall replace the provision in question with one or several valid provisions which can be 

30

 

enforced
and are as close as possible to the intent and economic purpose of such invalid of unenforceable provision. 

        H.    Assignment.    No assignment of this Agreement or of any rights or obligations hereunder may be made by Sellers
or Purchaser (by operation of law or otherwise) without the prior written consent of the other Party hereto, and any attempted assignment without the required consents shall be void,  provided, that
Purchaser shall have the right to assign this Agreement and/or any of its rights or obligations hereunder to any Affiliate of Purchaser
without prior written consent of Sellers, provided, further Purchaser shall remain obligated for all
Purchaser's obligations hereunder. This Agreement shall be binding upon and inure solely to the benefit of each Party hereto and their permitted transferees and nothing in this Agreement, express or
implied, is intended by or shall confer upon any other Person any rights, benefits or remedies of any nature whatsoever under or by reason of this Agreement. 

        I.    Third Party Intellectual Property.    Each Seller shall use commercially reasonable efforts to assign to the
Company all his right, title and interest in and to any Intellectual Property (as defined below) that such Seller has made or conceived (whether as a sole or joint inventor or as a joint inventor or
author, whether made within or outside working hours or upon the premises of the Company or elsewhere, as work for hire or otherwise) at any time while he has been an owner, employee or consultant of
the Company, to the extent such Intellectual Property has not already been assigned to the Company; provided, that neither Williams nor McGinity shall
be required to make any such assignment to the extent that (i) another Person has rights in or to such Intellectual Property or (ii) McGinity or Williams is under any obligation to
transfer, assign or hold such Intellectual Property to or for the benefit of any other Person. "Intellectual Property" means any information of a
technical and/or business nature such as ideas, discoveries, inventions, and trade secrets that directly relates to the Business or to any patents or patent applications of Company as of the date
hereof. 

        J.    Confidentiality.    The Parties acknowledge that the Confidentiality Agreement is in full force and effect. All
Confidential Information will be subject to the Confidentiality Agreement. Each Seller agrees to be bound by the terms and conditions of the Confidentiality Agreement the same as if such Seller were a
signatory thereto. 

        K.    Interpretation.    All references herein to Articles, Sections, Exhibits and Schedules shall be deemed
references to Articles and Sections of Exhibits and Schedules to this Agreement unless the context shall otherwise require. No inference in favor of or against any Party shall be drawn from the fact
that such Party has drafted any portion of this Agreement. The Parties have participated substantially in the negotiation, drafting, and revision of this Agreement with representation by counsel and
such other advisors, as they have deemed appropriate. The definitions set forth in this Agreement and its Exhibits and Schedules shall apply equally to both the singular and plural forms of the terms
defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neutral forms. 

        L.    Disclosure Schedules.    The inclusion of any information in the Disclosure Schedules shall not be deemed an
admission or acknowledgment, in and of itself and solely by virtue of the inclusion of such information in the Disclosure Schedules, that such information is required to be listed in the Disclosure
Schedules or that such items are material to the Company or the Sellers, as the case may be. The headings, if any, of the individual sections of each of the Disclosure Schedules are inserted for
convenience only and shall not be deemed to constitute a part thereof or a part of this Agreement. The disclosure of an item in one section of the Disclosure Schedules as an exception to a particular
representation or warranty shall be deemed to be a disclosure with respect to all other representations or warranties to the extent that the relevance of such item to such representations or
warranties is clear on the face of such item, notwithstanding the presence or absence of an appropriate section of the Disclosure Schedules with respect to such other representations or warranties or
an appropriate cross reference thereto. The specification of any dollar amount in the representations and warranties or 

31

 

otherwise
in this Agreement or in the Disclosure Schedules is not intended and shall not be deemed to be an admission or acknowledgment of the materiality of such amounts or items, nor shall the same
be used in any dispute or controversy between the Parties to determine whether any obligation, item or matter (whether or not described herein or included in any schedule) is or is not material for
purposes of this Agreement. 

        M.    Survival.    All representations, warranties, covenants and obligations in this Agreement, any certificate or
document delivered pursuant to this Agreement or any agreement made by a Seller or Purchaser related to Closing shall survive the Closing and the consummation of the contemplated transactions under
this Agreement as follows: (a) Sellers' covenants, representations and warranties related to fraud and the Exclude Representations and Warranties shall survive for the applicable statute of
limitations; all other covenants, representations and warranties of Seller shall survive for a period of eighteen (18) months from the Closing Date; and (b) Purchaser's covenants,
representations and warranties shall survive Closing for a period of five (5) years from the Closing Date, except for the covenants, representations and warranties of Purchaser contained in
Sections III.B.2, II.B.9, and IV.A, which shall survive for the applicable statute of limitations. 

        N.    Counterparts of the Agreement.    This Agreement may be executed and delivered (including by facsimile
transmission) in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties
and delivered to the other Parties, it being understood that all Parties need not sign the same counterpart. 

[Signature
Page Follows] 

32

Executed to be effective as of the date first written above. 

	 	 	SELLERS:
	

 	
 	

    
 Daniel J. Bates, Individually
	

 	
 	

    
 John J. Koleng, Jr., Individually
	

 	
 	

    
 Feng Zhang, Individually
	

 	
 	

    
 Michael M. Crowley, Individually
	

 	
 	

    
 James W. McGinity, Individually
	

 	
 	

    
 Robert O. Williams, III, Individually
	

 	
 	
PURCHASER:
	

 	
 	
LAB INTERNATIONAL INC.
	

 	
 	

By:	
 	

    

	

 	
 	

Its:	
 	

    

SIGNATURE PAGE TO THE

PURCHASE AND SALE AGREEMENT  

EXHIBIT A  

 Definitions  

        "Affiliate" means, as to any Person, any other Person that, directly or indirectly through one or more
intermediaries, controls, is controlled by, or is under common control with that Person. For purposes of this definition, "control" (including, with correlative meanings, the terms "controlled by" and
"under common control with"), as used with respect to any Person or group of Persons, means possession, directly or indirectly, of the power to direct or cause the direction of the management and
policies of the Person, whether through the ownership of voting securities, by contract, or otherwise. Notwithstanding the foregoing, in the case of Sellers, the term "Affiliate" shall not include any
Person unless at least a majority of the voting securities of the Person are owned, directly or indirectly through one or more intermediaries. 

        "Agreement" has the meaning given it in the opening paragraph of this Agreement. 

        "Assets" has the meaning given it in Section III.A.6. 

        "Assignment of Membership Interest" has the meaning given it in Section II.B.7. 

        "Breach" means, in the case of this Agreement or any other Contract, (i) any breach of or any inaccuracy in any representation or
warranty or any breach of or failure to perform or comply with any covenant or obligation under this Agreement or any other Contract (as applicable), or (ii) any event which, with the passing
of time or the giving of notice, or both, would constitute such a breach, inaccuracy or failure. 

        "Business" has the meaning given it in Preamble paragraph B. 

        "Business Day" means a day other than Saturday, Sunday or any other day on which banks located in Austin, Texas are authorized or
obligated to close. 

        "Cap" has the meaning given it in Section V.C.1.b. 

        "Closing" means the consummation of the transactions contemplated in this Agreement to occur on the Closing Date. 

        "Closing Date" has the meaning given it in Section II.A. 

        "Closing Value" has the meaning given it in Section I.C.2. 

        "Code" means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder. 

        "Company" has the meaning given it is paragraph A of the Preamble. 

        "Company Patents" has the meaning given it in Section III.A.17.a. 

        "Competing Business" has the meaning given it in Section IV.E.4.a. 

        "Competing Services" has the meaning given it in Section IV.E.4.b. 

        "Confidential Information" shall have the meaning given it in the Confidentiality Agreement. 

        "Confidentiality Agreement" means the Mutual Confidentiality Agreement, dated May 1, 2006, among the Purchaser and the Company. 

        "Contemplated Transactions" means all of the transactions contemplated by this Agreement, including without limitation: 

          (i)  the
sale of the Membership Interests by Sellers to Purchaser; 

         (ii)  the
execution, delivery, and performance of the Employment Agreements and the Consulting Agreements; 

        (iii)  the
performance by Purchaser and Seller of their respective covenants and obligations under this Agreement; and 

 

        (iv)  Purchaser's
acquisition and ownership of the Membership Interests. 

        "Condition of the Business" means the condition of the operations and assets of the Business and its financial condition as currently
operated by Sellers. 

        "Contract" means any written contract or agreement, including without limitation supply contracts, purchase orders, sale orders, bids,
customer agreements, mortgages, subcontracts, indentures, leases of personal property, deeds of trust, notes, guarantees, or conditional sales agreements to which the Person referred to is a Party and
which is related to the Business. 

        "Consulting Agreement" has the meaning given it in Section II.B.6. 

        "Damages" means all losses, penalties, fines, forfeitures, assessments, claims, suits, proceedings, demands, judgments, awards, taxes,
costs and expenses, including court costs, reasonable attorneys', accountants', consultants' and experts' fees and other costs and expenses incident to the transaction or proceedings or investigation
or the defense of any claim (whether or not litigation has commenced); provided, however, that Damages
do not include Special Damages. 

        "Deductible" has the meaning given it in Section V.C.1.b. 

        "Disclosure Schedules" means the written disclosure schedules of Sellers that are delivered to Purchaser on the date of this Agreement and
are identified as the Disclosure Schedules to this Agreement. 

        "Dispute" has the meaning given it in Section VII.A.1. 

        "Employee Benefit Plans" has the meaning given it in Section III.A.15. 

        "Employee Pension Benefit Plan" has the meaning given it in Section III.A.15. 

        "Employee Welfare Benefit Plan" has the meaning given it in Section III.A.15. 

        "Employment Agreement" has the meaning given it in Section II.B.6. 

        "Environmental, Health and Safety Laws" means all federal, state and foreign statutes and regulations relating to pollution or protection
of the environment, including without limitation the Comprehensive Environmental Response, Compensation and Liability Act, the Resource Conservation and Recovery Act, the Clean Air Act, the Clean
Water Act, and all federal, state and foreign statutes and regulations relating to safe and healthful working conditions and occupational safety and health hazards, and similar state statutes and
regulations, in each case as in effect as of the date hereof. 

        "ERISA" means the Employee Retirement Income Security Act of 1974, as amended, and the rules and regulations promulgated thereunder. 

        "Excluded Representations and Warranties" shall have the meaning given it in Section V.C.1.b. 

        "Expiration Date" means the date that is eighteen months after the Closing Date; provided,
that the Expiration Date for Indemnification Claims arising from fraud or Breach of the Excluded Representations and Warranties shall be the date given it in Section V.B.6. 

        "Financial Statements" has the meaning given it in Section III.A.12. 

        "FDA" means the United States federal Food and Drug Administration. 

        "First Program" has the meaning given it in Section I.D.1. 

        "GAAP" means generally accepted United States accounting principles, applied on a basis consistent with the basis on which the Financial
Statements were prepared. 

        "Geographic Area" has the meaning given it in Section IV.E.4.c. 

2

 

        "Governmental or Regulatory Authority" means any court, tribunal, arbitrator, authority, agency, commission, official or other
instrumentality of the United States, or any country, state, county, city or other political subdivision. 

        "Gross Revenue" has the meaning given it in Section I.D.2. 

        "Guaranteed Agreements" has the meaning given it in Section IV.H. 

        "Hazardous Materials" means any substance that has been defined by applicable Environmental, Health and Safety Law to be radioactive,
toxic, hazardous or otherwise a pollutant or contaminant, including without limitation PCBs, petroleum products or any fraction thereof, urea-formaldehyde and all substances listed as a
"hazardous substance," "hazardous waste," "hazardous material," or "toxic substance" or words of similar import, under any Environmental, Health and Safety Law. 

        "IND" has the meaning given it in Section I.D.1. 

        "Indemnification Claim" has the meaning given it in Section V.B.1. 

        "Indemnification Claim Notice" has the meaning given it in Section V.B.1. 

        "Intellectual Property" has the meaning given it in Section VIII.I. 

        "Interim Balance Sheet" means the statement of assets, liabilities and members' equity-modified cash and related statement of revenues,
expenses and retainer earnings-modified cash of the Company for the period ending October 31, 2006. 

        "Key Consultants" means each of James W. McGinity, Robert O. Williams, III and Daniel J. Bates. 

        "Key Employee" means each of John J. Koleng, Feng Zhang and Michael M. Crowley. 

        "Knowledge of Purchaser" means any fact, matter, occurrence or event that is actually known or that should be known after due inquiry by
Halvor Jeager, Andrew Reiter or Dr. Günter Knorr. 

        "Laws" means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of any Governmental or
Regulatory Authority. 

        "Leased Real Property" means that real property leased by the Company pursuant to the Office Building Lease Agreement dated
November 18, 2003 between the Company and JER/BRE Austin Tech, L.P. 

        "Leases" has the meaning given it in Section III.A.7. 

        "Liability" or "Liabilities" means any or all obligations (whether to make payments, to
give notices or to perform or not perform any action), commitments, contingencies and other liabilities of a Person (whether known or unknown, asserted or not asserted, whether absolute, accrued,
contingent, fixed or otherwise, determined or determinable, liquidated or unliquidated, and whether due or to become due). 

        "Lien" means any mortgage, pledge, security interest, hypothecation, assignment, lease, contractual or statutory lien, option, right of
use or possession of other Persons, right to seize, conditional sale contract, title retention contract, charge against any fee estate, condition to the fee estate, equitable interest in the fee
estate, right of way, easement, encroachment, servitude, right of first option, right of first refusal or similar restriction, including any restriction on use, transfer, receipt of income or exercise
of any other attribute of ownership or any other encumbrance. 

        "Licensed Patents" has the meaning given it in Section III.A.17.a. 

        "Material Adverse Effect" means any event, change or circumstance that, individually or with all related events, changes or circumstances,
has had or would be reasonably likely to have a material 

3

 

adverse
effect on the Business or the Condition of the Business; provided, however, that any adverse
effect resulting from any events, changes or circumstances that are generally applicable to and arise or result from (i) the industries and markets in which the Business is conducted;
(ii) general economic, political or financial market conditions; (iii) changes after the Closing Date in any applicable Law or in the interpretation of any applicable Law;
(iv) the outbreak or escalation of hostilities involving the United States, the declaration by the United States of a national emergency or war or the occurrence of any other calamity or
crisis, including acts of terrorism; (v) the disclosure of the fact that Purchaser is the prospective acquirer of Company; (vi) the announcement or pendency of the transactions
contemplated by this Agreement or any other Related Agreement; (vii) any change in accounting requirements or principles imposed upon Company or the Business; (viii) actions taken by
Purchaser or its Affiliates; or (ix) compliance with the terms of, or the taking of any action required by, this Agreement or any other Related Agreement shall be excluded from the
determination of whether a Material Adverse Effect has occurred or would be reasonably likely to occur. 

        "Material Contracts" has the meaning given it in Section III.A.18.a. 

        "Membership Interest" has the meaning given it in paragraph C of the Preamble. 

        "Order" means any writ, judgment, decree, injunction, award or other order of any Governmental or Regulatory Authority. 

        "Ordinary Course of Business" means an action taken by a Person will be deemed to have been taken in the "Ordinary Course of Business"
only if: 

        (1)   such
action is consistent with the past practices of such Person and is taken in the ordinary course of the normal day-to-day operations of such
Person; 

        (2)   such
action is not required to be authorized by the board of directors of such Person (or by any Person or group of Persons exercising similar authority); and 

        (3)   such
action is similar in nature and magnitude to actions customarily taken, without any authorization by the board of directors (or by any Person or group of Persons
exercising similar authority), in the ordinary course of the normal day-to-day operations of other Persons that are in the same line of business as such Person. 

        "Organizational Documents" means (a) the articles or certificate of incorporation and the bylaws of a corporation;
(b) the articles of organization or certificate of formation and the operating agreement or limited liability company agreement, or similar documents governing a limited liability company,
(c) any agreement made and any charter or similar document adopted or filed in connection with the creation, formation, or organization of a Person; and (d) any amendment to any of the
foregoing. 

        "Party" and "Parties" have the meaning given it in the opening paragraph of the Agreement. 

        "Patents" has the meaning given it in Section III.A.17.a. 

        "Pension Benefits Act" means the Pension Benefits Act, as amended. 

        "Percentage Interest" means, with respect to each Seller, the percentage set forth opposite such Seller's name in Section III.A.3. 

        "Permits" means all licenses, permits, authorizations, approvals, registrations, franchises and similar consents granted or issued by any
Governmental or Regulatory Authority. 

        "Permitted Lien" means (i) Liens for current Taxes not yet due or Taxes being contested in good faith and for which adequate
reserves have been established, (ii) mechanics', materialmen's, warehousemen's, contractors', workers', repairmen's, carriers' and similar Liens attaching by operation of law, incurred in the
Ordinary Course of Business, and securing payments not delinquent or payments 

4

 

which
are being contested in good faith, (iii) the rights, if any, of third party suppliers or other vendors having possession of Assets in the Ordinary Course of Business, (iv) Liens or
other exceptions to title listed on Disclosure Schedule III.A.6, if any, and (v) Liens that do not materially detract from the value or use of the Assets as presently used. 

        "Person" means any natural person, corporation, general partnership, limited partnership, limited liability partnership, limited liability
company, proprietorship, other business organization, trust, Governmental or Regulatory Authority, or other entity. 

        "Phase I" has the meaning given it in Section I.D.1. 

        "Phase I Triggering Event" has the meaning given it in Section I.D.1. 

        "Phase II Triggering Event" has the meaning given it in Section I.D.2. 

        "Phase III Triggering Event" has the meaning given it in Section I.D.3. 

        "Proceedings" means any action, notice of violation, arbitration, audit, hearing, investigation, litigation or suit (whether civil,
criminal, administrative, judicial or investigative, whether formal or informal, whether public or private) commenced, brought, conducted or heard by or before, or otherwise involving, any
Governmental or Regulatory Authority or arbitrator. 

        "Products" means any products or services of the Business. 

        "Public Record" has the meaning given it in Section III.B.8. 

        "Purchase Price" has the meaning given it in Section I.B. 

        "Purchaser" has the meaning given it in the opening paragraph of this Agreement. 

        "Purchaser Common Stock" has the meaning given it in Section I.C.2. 

        "Records" means information that is inscribed on a tangible medium or that is stored in an electronic or other medium and is retrievable
in perceivable form. 

        "Related Agreements" means all agreements, certificates, instruments or other documents required to be executed and/or delivered pursuant
to or in connection with this Agreement by any Person. 

        "Resignations" has the meaning given it in Section II.B.9. 

        "Schedules" means the written schedules of Sellers that are delivered to Purchaser on the date of this Agreement and are identified as the
Schedules to this Agreement. 

        "Seller" and "Sellers" have the meanings given it in the preamble. 

        "Sellers' Knowledge," "Knowledge of Sellers" and "Known to
Sellers" means any fact, matter, occurrence or event that is actually known or that should be known after due inquiry by Sellers or any one of them. 

        "Software Licenses" has the meaning given it in Section III.A.17.g. 

        "Solvent" means with regard to a Person, that: 

          (i)  the
fair saleable value of the property of the Person is, on the date of determination, greater than the total amount of liabilities (including contingent and
unliquidated liabilities) of the Person and its subsidiaries as of such date, 

         (ii)  on
the date of determination, the Person and its subsidiaries are able to pay all of their liabilities and debts as such liabilities and debts mature or become due in
the usual course of business, 

5

 

        (iii)  the
Person and its subsidiaries do not have unreasonably small capital for conducting their respective businesses as presently conducted or as proposed to be conducted
by them, 

        (iv)  the
Person and its subsidiaries do not intend to, nor do they believe that they will, incur debts beyond their ability to pay such debts as they mature, and 

         (v)  In
computing the amount of contingent or unliquidated liabilities at any time, such liabilities will be computed as the amount which, in light of all of the facts and
circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability. 

        "Special Damages" means all damages that are not recoverable at law as direct damages for the claim in question and include, without
limitation, indirect damages, incidental damages, consequential damages, exemplary damages, lost profits and punitive damages. Special Damages also include any damages measured by any multiple of
earnings or other valuation method premised on the value or claimed diminution in the value of the Business as a whole or damages for loss of business opportunity. Special Damages also include any
increased operational costs incurred as a result of compliance with any settlement of any such matter. Notwithstanding the inclusion of incidental damages in the foregoing definition, Special Damages
do not include incidental damages that are expressly included in the definition of Damages, such as reasonable attorneys fees and costs of investigation or defense of a claim. 

        "Taxes" means all United States federal, state, local, foreign, and other net income, gross income, gross receipts, social security,
sales, use, ad valorem, franchise, capital gains, withholding, payroll, employment, unemployment, social security, excise, property, and any and all other taxes, assessments, fees or other similar
governmental charges, whether computed on a separate, consolidated unitary, combined or any other basis together with any interest and any penalties, additions to tax, estimated taxes or additional
amounts with respect thereto, and the term "Tax" means any one of the foregoing Taxes. 

        "Tax Proceeding" has the meaning given it in Section III.A.22.b. 

        "Tax Returns" means all returns, declarations, reports, statements, schedules, notices, forms or other documents or information required
to be filed in respect of the determination, assessment, collection or payment of any Tax or in connection with the administration, implementation or enforcement of any Tax, and the term "Tax Return"
means any one of the foregoing Tax Returns. 

        "Third Party Action" has the meaning given it in Section V.B.2. 

        "Third Party Claim" has the meaning given it in Section V.B.2. 

        "Third Party Claim Notice" has the meaning given it in Section V.B.2. 

        "Trade Secrets" means all know-how, trade secrets, confidential or proprietary information, customer lists, technical
information, data, process technology, plan, drawing and blue prints to the extent same constitute "trade secrets" under applicable Law. 

        "Trademarks" has the meaning given it in Section III.A.17.b. 

        "TSX" means the Toronto Stock Exchange. 

        "Transfer Taxes" means all sales, use, goods and services taxes, harmonized sales, transfer, reporting, recording, filing, and other
similar fees, taxes and charges arising out of or in connection with the transactions effected pursuant to this Agreement. 

        "Year End Financial Statements" has the meaning given it in Section III.A.12. 

6

EXHIBIT II.B.6-A  

Form
of Employment Agreement 

EXHIBIT II.B.6-B  

Form
of Consulting Agreements 

EXHIBIT II.B.7  

Form
of Assignment of Membership Interests 

EXHIBIT IV.E.3  

Allowed
Activities 

        Robert
O. Williams, III and James W. McGinity are professors at The University of Texas and senior officers in PharmaForm, L.L.C. They have successful careers as professors at
U.T. where they team teach undergraduate and graduate courses in pharmaceutics and direct graduate students and post doctoral scientists in their respective research programs. The results from this
work are presented at national and international conferences and then published in peer reviewed journals. They also serve as consultants to the chemical, biotech and pharmaceutical industry and serve
as members of scientific advisory boards for some of these companies. Drs. McGinity and Williams also serve as expert witnesses in patent litigation cases. These activities have resulted in
research grants to the University and, in many cases, funded research projects for PharmaForm. At PharmaForm, they develop business relationships, help recruit new clients, meet with client company
representatives in Austin or at the client's home site, meet with PharmaForm personnel on company projects, write and review proposals and consult with PharmaForm scientists on technical issues. 

QuickLinks

Exhibit 10.4

PURCHASE AND SALE AGREEMENTQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.5    
    

Confidential Treatment Requested

 
 

EXCLUSIVE LICENCE, DEVELOPMENT AND SUPPLY
  AGREEMENT    
    

        THIS AGREEMENT is made this 20th day of June 2007 BETWEEN 

        JANSSEN PHARMACEUTICA NV, a company organized and existing under the laws of Belgium and having its registered office at Turnhoutseweg 30,
2340 Beerse, Belgium, (hereinafter referred to as "JANSSEN") 

        AND

        1.     LAB INTERNATIONAL SRL, a company organized and existing under the laws of Barbados and having an office at Windmark, Harts
Gap, Christ Church, Barbados, West Indies (hereinafter referred to as "LAB SRL") and 

        2.     LAB PHARMA OY, a company organized and existing under the laws of Finland and having an office at Biolinja 12, 20101
Turku, Finland (hereinafter referred to as "LAB OY"); 

together
"LAB" 

and
all together "the Parties" 

RECITALS

        WHEREAS
LAB OY has developed a specific reservoir metered dose dry powder inhaler (the Device, as further defined below). This Device is, together with the formulation technology, a
platform for pulmonary drug delivery, and is protected by Patents and Know-How (both as defined below). Further LAB OY and LAB SRL have developed, by using the Device, a pharmaceutical
product for pulmonary administration of fentanyl citrate formulations for the treatment of pain (the Product, as further defined below) that is currently undergoing clinical trials, 

        WHEREAS
JANSSEN is committed to undertake development, marketing and sale of the Product in the Territory under the terms and conditions of this Agreement and 

        WHEREAS
JANSSEN and LAB now wish to enter into an exclusive licence agreement with regard to the Patents, Know-IIow and LAB Trademarks (as defined below) and into an
exclusive development and supply agreement with regard to the Product; 

        NOW,
THEREFORE, in consideration of the above recitals and the mutual covenants and obligations set forth herein, the Parties hereby agree as follows: 

1.     Definitions  

        In this Agreement the following words and phrases shall have the meanings set out opposite them: 

	1.1
	"Additional
Indication" shall mean any and all medical indications of the Product other than the First Indication;

	1.2
	"Affiliate"
shall mean, with respect to either Party, any corporation, company, partnership, joint venture or any other entity which, directly or indirectly, controls or is controlled
by, or is under common control with such Party. For the purposes of this definition, "control" shall mean direct or indirect ownership of fifty percent (50%) or more of the stock or shares entitled to
vote for the election of directors;

	1.3
	"Agreement"
shall mean this Exclusive Licence, Development and Supply Agreement and its Schedules, as may be updated or amended from time to time;

	1.4
	"CHMP"
shall mean EMEA`s Committee for Medicinal Products for Human Use; 

* * * Confidential Treatment Requested * * *

 
	1.5
	"current
Good Manufacturing Practice" or "cGMP" shall mean the current good manufacturing guidelines set out in the United States Code of Federal Regulations Parts 210 and 211, United
States 21CFR Part 820 Quality System Requirements and in EU Directive 2003/94/EC and ISO 13485 so far as the same are relevant in each case as amended and updated from time to time;

	1.6
	"current
Good Clinical Practice" or "cGCP" shall mean the current guidelines for the principles of good clinical practice in the conduct of clinical trials on medicinal products for
human use as set out in EU Directive 2001/20/EC and US Guidance for Industry E6 Good Clinical Practice so far as the same are relevant in each case as amended and updated from time to time;

	1.7
	"current
Good Laboratory Practice" or "cGLP" shall mean the current guidelines for the principles of good laboratory practice as set out in the EU Directives 2004/9/EC and 2004/10/EC
and the related OECD principles and FDA's GLP regulations so far as the same are relevant in each case as amended and updated from time to time;

	1.8
	"Confidential
Information" shall mean information which is transferred between the Parties by written or other tangible form and clearly marked as being confidential by the disclosing
Party. In the case of information which is disclosed orally, Confidential Information includes such information which is confirmed thereafter within thirty (30) days in writing or other
tangible form by the disclosing Party as confidential. The term Confidential Information shall include but not be limited to, all Product Specifications and manufacturing specifications, and
information relating to the market or technology or either Party's business provided by it in connection with this Agreement; Know-How revealed shall be deemed to be Confidential
Information, regardless of its marking as confidential or not; 

The
term Confidential Information shall also include information disclosed by JANSSEN and LAB International Inc. under the agreement of July 28, 2005 which shall also be applicable for
the Parties of the present Agreement; 

The
term Confidential Information shall not mean any information which is previously known to the receiving Party without obligation of confidence to the disclosing Party, as shown by its written
records, or which, without breach of this Agreement, is publicly disclosed either prior or subsequent to receipt by the receiving Party of such Confidential Information, or which is subsequently
received by the receiving Party from a Third Party not under an obligation of confidence to the disclosing Party, or which is independently developed by a Party without violation of any
confidentiality requirements or intellectual property rights hereunder, or disclosure of which is required by subpoena or other legal or administrative process or by law, provided that, with respect
to the latter, the Parties shall closely collaborate in order to obtain a protective order or other appropriate remedy concerning any such disclosure; if any such order or other remedy does not fully
preclude disclosure Parties shall make such disclosure only to the extent that such disclosure is legally required; 

	1.9
	"Development
Plan" shall mean the plan, as agreed by the Parties and set out in Schedule A as amended from time to time,
specifying all the development work, including goals, directions, activities, due dates for the non-clinical and clinical program, the clinical trial program for the development of the
First Indication, the implementation of agreed upon additional features into the Product, and regulatory preparations, to be performed mainly by LAB including completion of the regulatory file for the
Product in a form suitable for submission to the Regulatory Authority and as requested by JANSSEN, with the objective of obtaining a Marketing Authorisation for the First Indication in the European
Union;

	1.10
	"Development
Period" shall mean the period until the First Marketing Authorization has been obtained; 

* * * Confidential Treatment Requested * * *

2

 
	1.11
	"Device"
shall mean a reservoir metered dose dry powder inhaler for the pulmonary delivery of multiple doses of a dry powder formulation of certain compounds;

	1.12
	"Documented
Manufacturing Cost" shall mean costs in accordance with GAAP (Generally Accepted Accounting Principles), which are reasonable and necessary, in each case linked to a
commercial sale and comprise: 

* * *  

* * * Confidential Treatment Requested * * *

3

 

* * *  

	1.13
	"Effective
Date" shall mean the last date of execution of this Agreement;

	1.14
	"EMEA"
shall mean the European Medicines Evaluation Agency and any successor entity;

	1.15
	"FDA"
shall mean the US Food and Drug Administration and any successor entity;

	1.16
	"Field"
shall mean the pulmonary administration to humans of fentanyl, alfentanil, sufentanil or remifentanil in base or salt form, in particular fentanyl citrate, or the
stereoisomers, solvates, non-covalent complexes, chelates, polymorphs or amorphous forms thereof;

	1.17
	"First
Commercial Sale" shall mean the first sale of the Product by JANSSEN or its designees in any country in the Territory following receipt of the Marketing Authorisation; 

Any
sales made prior to the receipt of the Marketing Authorization, such as so-called "named patient sales", "compassionate use" sales and the like, shall not be deemed First Commercial
Sales; 

	1.18
	"First
Indication" shall mean the first medical use for the Product approved in a European Marketing Authorisation for the management of breakthrough pain in cancer patients who are
already receiving and who are tolerant to opioid therapy for their cancer pain;

	1.19
	"Force
Majeure Event" shall mean causes beyond a party's control, including, without limitation the following which, for the purposes of this Agreement, shall be regarded as beyond
the control of the Party in question; act of God, acts or omissions of any government or any rules, regulations or orders of any govermnental authority or any officer, department, agency or instrument
thereof; fire, storm, flood, earthquake, accident, acts of the public enemy, war, rebellion, insurrection, riot, invasion, strikes or lockouts; 

* * * Confidential Treatment Requested * * *

4

 
	1.20
	"Global
Safety Database" ("GSD") shall mean the database containing all Adverse Events and pregnancy reports for the Product that will be used for regulatory reporting and responses
to safety queries from Regulatory Authorities. Adverse Event (AE) shall have the official meanings or definitions as provided by and as further defined or modified by the applicable law and Regulatory
Authorities;

	1.21
	"Improvement"
shall mean 

* * *  

	1.22
	"JANSSEN
Trademark" shall mean any trademark, commercial name, logo and/or other distinctive sign owned by JANSSEN or a JANSSEN Affiliate and chosen by JANSSEN for use with the
Product;

	1.23
	"Joint
Improvements" shall mean Improvements that include at least one inventor with an obligation to assign rights to LAB and at least one inventor with an obligation to assign
rights JANSSEN;

	1.24
	"Know-How"
shall mean any and all unpatented or unpublished inventions, discoveries, trade secrets, information, data, analysis, formulae, procedures, methods, processes
and results, or any other know-how in the possession of LAB which relates to or is useful in connection with the development, approval and eventual commercialization of the Product or
developed by LAB in the performance of this Agreement, including clinical, pre-clinical, and regulatory information concerning the Product;

	1.25
	"LAB
Trademark" shall mean any trademark, commercial name, logo and/or other distinctive sign owned by LAB (as listed in  Schedule K) and chosen by JANSSEN or an Affiliate for use with the Product;

	1.26
	"Manufacturing"
shall mean all steps leading to and including the preparation of the powder formulation, filling of the formulation in the subassembly of the Device, the final
assembly of the Device post filling, secondary packaging of the Product, all Product testing required for quality control, quality, assurance and warehousing;

	1.27
	"Manufacturing
Equipment" shall mean the single and multi-cavity production injection moulding tools and assembly/testing modules, filling and packaging equipment for Manufacturing
the Product and all equipment and fixtures necessary for control of Product quality;

	1.28
	"Manufacturing
Plan" shall mean the plan set out in Schedule F as amended from time to time, specifying all activities and
associated due dates for the design, establishment, validation and operation of the manufacturing facilities and procedures for the Manufacturing of the Product for the supply of the Product to
JANSSEN;

	1.29
	"Marketing
Authorisation" or "MA" shall mean any approval of the Product and/or establishment license, registration or authorization of any agency, department or other governmental
entity having regulatory jurisdiction, required for the manufacture, storage, import, export, transport or commercial sale or use of the Product for use in the Field in any country of the Territory; 

* * * Confidential Treatment Requested * * *

5

 
	1.30
	"Marketing
Authorisation Application" or "MAA" shall mean the application for a Marketing Authorization;

	1.31
	"Net
Sales" shall mean, commencing with the First Commercial Sale of the Product in any country in the Territory, the aggregate of the gross invoiced sales price for the Product sold
by JANSSEN or its designees to Third Parties, after deduction of the following amounts according to standard method of accounting and to the extent included in the gross invoice amount: 

* * *  

	1.32
	"Patents"
shall mean the patents listed in Schedule K and any patents (including all additions, divisions, continuations,
continuations-in-part, substitutions, national patent rights, extensions, patent term extensions, supplementary protection certificates and renewals thereof), utility models
and patent applications (including patents issued thereon) deriving or claiming priority from any of the patents and patent applications that are or become owned or licensed by LAB and that would be
infringed (or, in the case of patent applications, contain claims which, if allowed in an issued patent, would be infringed) by the development, use or sale of the Product in the absence of the
licences granted herein;

	1.33
	"Price"
shall mean the price charged by LAB SRL to JANSSEN for the Product, net of VAT, as set out in Schedule I and
Section 15.3;

	1.34
	"Product"
shall mean the Device containing 30 doses of powder formulation of fentanyl citrate in two separate strengths of 100 and 200 micrograms per dose developed and owned by LAB
as specified in Schedule B, and any Improvements thereto;

	1.35
	"Recall"
shall mean the voluntary or forced recall of the Product from the market and "Recalled Product" shall mean Product which is the subject of a Recall;

	1.36
	"Regulatory
Authorities" shall mean EMEA, the CHMP, the MHRA and other national regulatory authorities responsible for granting MAs for pharmaceutical products in or outside the
Territory and the FDA with respect to the Manufacturing and supply of the Product from the United States of America;

	1.37
	"Royalty"
shall have the meaning set out in Schedule I;

	1.38
	"Scale
Up Plan" shall mean the plan set out in Schedule G; as amended from time to time, specifying all activities and
associated due dates for scale-up of the LAB manufacturing facilities to a commercial scale operation with capacity to meet the forecasted demand for the Product; 

* * * Confidential Treatment Requested * * *

6

 
	1.39
	"Scientific
Advice" shall mean Scientific Advice from CHMP concerning the requirements for a MA for the Product for the First Indication within the EU;

	1.40
	

* * *  

	1.41
	"Subcontractor"
shall mean a Third Party performing a Manufacturing step for the Product under contract to LAB;

	1.42
	"Supplier"
shall mean a Third Party, other than a Subcontractor, supplying API, excipients, raw materials; Devices, primary and secondary packaging components, equipment or services
for Manufacturing the Product;

	1.43
	"Term"
shall mean the longest of (a) ten (10) years from the date of the First Commercial Sale of the Product in the Territory or (b) the expiration of the longest
lasting LAB Patent related to the Product or (c) the expiration of longest lasting regulatory exclusivity for the Product in the Territory;

	1.44
	"Territory"
shall mean European Union's current 27 member states plus Switzerland, Norway, Iceland, Liechtenstein, Russia, CIS (Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan,
Kyrgyzstan, Moldova, Tajikistan, Ukraine, Uzbekistan and as associate member Turkmenistan), Croatia, the former Yugoslav Republic of Macedonia (FYROM), Bosnia-Herzegovina, Serbia, Montenegro, Turkey,
Andorra, San Marino, Monaco, all the countries of the African continent, all the Middle East
countries                                * * *                                Sri Lanka
and Pakistan;

	1.45
	"Third
Party" shall mean any person, corporation, or other entity other than JANSSEN, LAB and their respective Affiliates;

	1.46
	"Training
Sample" shall mean a version of the Product not containing any active pharmaceutical ingredient designed and provided for demonstration purposes, education and training of
health care professionals, patients and others in the use of the Product. 

        In
this Agreement, the singular may, where the context so requires, include the plural, the masculine shall include the feminine and vice-versa. References to sections,
schedules and to headings are references to sections, schedules and to headings of this Agreement, unless otherwise stated, and are included for convenience only; in the case of any conflict between
the provisions of any Section or schedule, then the provisions of the Section shall prevail. 

I.     LICENCE  

2.     Grant of Licence, Improvements, right of first negotiation and payments  

	2.1
	LAB
OY hereby grants to JANSSEN an exclusive licence in the Field under the Patents, Know-How and LAB Trademarks to develop, make (both subject to Section 11.3
below), use, market, sell, promote and distribute the Product in the Territory, subject to the terms and conditions set forth in this Agreement. JANSSEN shall have the right to sublicense. For the
avoidance of doubt and except as expressly stated otherwise in this Agreement, LAB has not reserved the right, beyond its rights and obligations to perform the present Agreement, to develop, make,
use, market, sell, promote or distribute the Product itself, whether directly or indirectly in the Territory.

	2.2
	Without
prejudice to JANSSEN's exclusivity for the Product in accordance with Section 2.1, LAB shall be entitled to develop and manufacture (i) the Device in the
Territory for use by LAB or Third Parties in or outside the Territory and (ii) the Product in the Territory for use by LAB or Third Parties outside the Territory. 

* * * Confidential Treatment Requested * * *

7

 
	2.3
	Titles,
rights and ownership to any and all Improvements, whether patented or not, obtained as a result of the development of the Product shall be owned by the Party/Parties that
has/have developed the Improvement. In case of (i) Improvements made solely by LAB and (ii) Joint Improvements, LAB will grant to JANSSEN an exclusive, royalty-free and sub-licensable
licence in the Field in the Territory. In the case of Improvements made solely by JANSSEN and Joint Improvements, JANSSEN shall, if such improvements cannot be used separately from the Product, grant
to LAB a royalty free non-exclusive licence in the Field outside the Territory (and, for Manufacturing and Development also inside the Territory). If and to the extent that such improvements can be
used separately from the Product, JANSSEN shall grant to LAB a royalty free non-exclusive licence in and outside the Field and in and outside of the Territory and LAB shall use such licence without
prejudice to JANSSEN's exclusivity for the Product in accordance with Section 2.1. 

* * *  

	2.4
	Improvements
that are made by employees of a Party shall, to the maximum extent permitted by the law governing such employee inventions, be demanded by the employing Party from the
inventing employee. The Parties shall discuss whether or not the Improvement should be kept in confidence as a trade secret or be protected through an application for a Patent or other formal
protection.

	2.5
	JANSSEN,
for a period ending two (2) years after the month that follows the First Commercial Sale of the Product withing the Territory, has a right of first negotiation to extend the
exclusive licence to territories other than the Territory. 

* * *  

Kong
and Taiwan) or Japan. If JANSSEN fails to exercise its matching right in due time, the right of first negotiation shall be void. 

	2.6
	If
JANSSEN wishes to extend the Territory, JANSSEN shall send LAB a written notification with detailed information about the extension. The Parties then shall enter into bona fide
discussions. 

* * *  

	2.7
	In
consideration of the rights granted by LAB and its development work and studies on the Device and the Product, the following payments ("Milestone Payments") are due and payable by
JANSSEN within 30 days of receipt of an
invoice                                * * *                                following the specified event. Each payment is due
only
once. 

* * * Confidential Treatment Requested * * *

8

  

* * *  

	2.8
	Any
income or other taxes which JANSSEN is required by law to pay or withhold on behalf of LAB with respect to any payments payable to LAB under this Agreement shall be deducted from
the amount of such payments due. JANSSEN shall furnish LAB with proof of such payments. Any such tax required to be paid or withheld shall be an expense of and borne solely by LAB. JANSSEN shall
promptly provide LAB with a certificate or other documentary evidence to enable LAB to support a claim for a refund or a foreign tax credit with respect to any such tax so withheld or deducted by
JANSSEN. Both parties will reasonably cooperate in completing and filing documents required under the provisions of any applicable tax treaty or under any other applicable law, in order to enable
JANSSEN to make such payments to LAB without any deduction or withholding. If JANSSEN had a duty to withhold taxes in connection with any payment it made to LAB under this Agreement but JANSSEN failed
to withhold, and such taxes were assessed against and paid by JANSSEN, then LAB will indemnify and hold harmless JANSSEN from and against such taxes. VAT (or equivalent), if any, shall be added to the
Price. 

3.     * * *

	3.1
	Whenever
LAB has the intention to develop a                                *
* *                                in or outside the Territory,
LAB shall submit such
intention together with a development project proposal without undue delay to JANSSEN. Such proposal shall refer to the planned territory of use and to the device as planned for JANSSEN's review. LAB
shall also give JANSSEN an exclusive option to receive licences for intellectual property rights or know-how on
the                                * *
*                                for the Territory and in the
Field, if any.

	3.2
	In
the event that JANSSEN agrees to proceed with the development of the                * * *                for the Territory and in
the Field according to the agreed upon                * * *                Development Project, JANSSEN shall be responsible for the cost of any
pharmaceutical, preclinical and clinical trial development related to the                * * *                Product (but not the device
used) and LAB will be responsible for the cost of any licence fee, milestones, royalties or other payments, if any, to a Third Party licensor for the device with which the
                * * *                Product will be developed.

	3.3
	In
the event that JANSSEN decides at its sole discretion not to proceed with the proposed development of the                * *
*                Product for use in the Territory in the Field then LAB shall have the right to start or continue the development of the
                * * *                Product in or outside the Territory. LAB shall however not have the right to develop or license the
                * * *                Product for use in the Territory other than by the prior express written permission of JANSSEN. 

* * * Confidential Treatment Requested * * *

9

 
	3.4
	Should
JANSSEN decide to proceed with the                * * *                Product, JANSSEN has the right of first negotiation
outside the Territory as set out in Section 2.5 and 2.6.

	3.5
	The
Parties shall agree on terms for the development of a                * * *                Product along the lines of this
Agreement. 

II.    PRODUCT DEVELOPMENT—REGULATORY APPROVAL—COMMERCIAL EFFORTS  

4.     Product Development  

	4.1
	

* * *  

	4.2
	At
the latest thirty (30) days of the Effective Date, the Parties shall establish a Joint Development Team ("JDT"). The JDT shall be comprised of six members as follows: three
(3) representatives of each Party to be chosen at each Party's entire discretion, but preferably including specialists from pharmaceutical, clinical, regulatory and manufacturing management.
Meetings of the JDT shall be held to the extent deemed necessary by the JDT and at locations as determined by the JDT but not less than four (4) meetings a year shall be held. Each party shall
have the right to request a JDT meeting with seven (7) days prior written notice if the need arises. The Parties shall bear their respective expenses in attending the meetings of the JDT.

	4.3
	The
JDT shall (i) coordinate, review and update the development activities as set forth in the Development Plan (including timings for finalizing each of the steps of the
Product development) and ensure that there is productive collaboration between the Parties, (ii) evaluate the scientific, technical and commercial feasibility of the proposed works and studies,
the safety of the Product and regulatory material for the further development of the Product in the Territory and (iii) evaluate Manufacturing and supply readiness of the Product. The Parties
acknowledge that the risk management and safety features of the Product will be an essential part of the discussions of the JDT.

	4.4
	

* * *  

	4.5
	Decisions
shall be made by the JDT by consensus after an open discussion. Regardless of the number of representatives from each Party, each Party shall present one consolidated view
on any issue in dispute. If the JDT fails to reach unanimous agreement on any matter, the decision of JANSSEN will be final and determinative. 

The
JDT shall review the Development Plan on a quarterly basis and will modify said Development Plan as required. The JDT shall not decide on changes of the Product Specifications, nor on Improvements
of the Product nor on changes of the Agreement. 

Notwithstanding
the foregoing, decisions made by JANSSEN which may increase the costs for the specific part of execution of the Development Plan by more than 10% for LAB due to requirements from
JANSSEN beyond the requirements as known and/or asked by the CHMP or other Regulatory Authorities shall not be binding for LAB unless JANSSEN agrees to bear such costs. In such event, LAB shall
substantiate and fully disclose to JANSSEN the base budget as well as the anticipated cost increase. 

* * * Confidential Treatment Requested * * *

10

 
	4.6.
	Whether
or not included in the Development Plan, LAB shall be responsible for the conduct and costs of all pharmaceutical development, pre-clinical and clinical studies
necessary to obtain the applicable MA for the First Indication of the Product in the European Union within the agreed timelines as included in the Development Plan. JANSSEN shall, at its sole
discretion, assist LAB during the development at its own costs. 

* * *  

Any
event that occurs in the execution of the Development Plan that is likely to result in a delay of more than                * * *                
shall be disclosed by LAB to JANSSEN without undue delay. Upon request by JANSSEN, the Parties shall organize a JDT meeting immediately to discuss such event and agree on a plan for appropriate
countermeasures, if applicable. 

Any
event that occurs in the execution of the Development Plan, whether or not caused by a Force Majeure event, and which is likely to lead to the delay of the MAA filing more than
                * * *                JANSSEN shall have the right to take over the ongoing and planned development, studies and trials but only after
prior reasonable consultation of such consequences by the JDT. In the case of JANSSEN taking over the ongoing and planned development, studies and trials, JANSSEN's reasonable costs in performing or
having such development, studies and trials performed, shall be fully credited against any future milestone payments payable to LAB according to section 2.7. 

The
right of JANSSEN to take over the development is excluded for such deviations which are approved by the JDT. 

	4.7
	JANSSEN
shall be responsible for the costs of all additional pharmaceutical development, pre-clinical and clinical studies, all of them to the extent necessary, and
regulatory processes (including pricing and reimbursement negotiations, as set out in Section 6.1), as required for obtaining Marketing Authorisations for (i) the First Indication of the
Product in the non-EU Territory and (ii) any Additional Indications for the Product in the Territory. For all such pharmaceutical development and pre-clinical and
clinical studies, to the extent they are deemed reasonably necessary to JANSSEN, the Parties shall make a separate development plan and LAB shall promptly offer JANSSEN reasonable assistance in
preparation and execution of the development plan and JANSSEN will reimburse LAB as set forth in Schedule I. LAB shall strictly adhere to the agreed timelines and shall provide all clinical
trial materials at cost. If LAB, its Affiliates or Third Parties acting on behalf of LAB do not have adequate resources or capabilities to reasonably meet JANSSEN's requirements, then JANSSEN shall be
entitled to have the work performed by a Third Party Contract Research Organisation and in the latter event, LAB shall offer reasonable assistance at JANSSEN's request and expense. In that case,
JANSSEN shall inform LAB about the respective development steps and give LAB access and the right to use such information subject to JANSSEN's contractual obligations towards Third Parties.

	4.8
	LAB
will assign adequate personnel to perform its obligations under this Agreement during the Development Period. 

* * * Confidential Treatment Requested * * *

11

 
	4.9
	LAB
shall, for additional development work identified under Section 4.7, use all reasonable efforts (JANSSEN giving LAB reasonable notice of its requirements) to provide to
JANSSEN all Products needed to carry out the development plan and provide all clinical trial supplies at cost.

	4.10
	The
JDT shall dissolve after completion of the Development Period. 

5.     Product Improvements  

	5.1
	From
time to time during the Term, either Party may submit to the other written proposals for the development, adoption and implementation of any Improvement of the Product. The
Parties shall exercise commercially reasonable efforts to review such proposed change with each other without undue delay and, if and when Parties agree in writing on the proposed Improvement and the
plan for its implementation, the change shall become effective, subject to any additional regulatory or other approval necessitated by such change, in which case it shall only become part of the
Product Specification when such approvals for implementation of such Improvements have been obtained and notified to JANSSEN by EMEA and any other relevant Regulatory Authorities. If the Parties agree
on the implementation of any such Improvement to the Product, they shall modify the Schedule B to reflect the same.

	5.2
	All
decisions regarding any Improvement shall only be made after the Parties have agreed upon the calculation of costs of the implementation of such Improvement, the cost of
manufacturing and the implications for the Price, if any. Except as agreed otherwise, LAB shall bear the cost for the development of any Improvement.

	5.3
	For
the avoidance of doubt, in no event shall any Improvement (or any change or modification to the Product Specification) of the Product in the Territory be notified to Regulatory
Authorities or be implemented or made without the prior written approval of both Parties. 

6.     Regulatory Strategy Procedures and Approval  

	6.1
	

* * *  

	6.2
	

* * *  

Except
if expressly agreed otherwise, pricing and reimbursement of the Product shall at all times exclusively be handled by JANSSEN. 

	6.3
	As
indicated in Section 4.6, LAB shall, at its cost and expense, follow the Scientific Advice and provide all necessary samples, information, documentation and data and prepare
the regulatory file according to the Regulatory Authorities' rules and guidelines and in agreement with JANSSEN, in a manner suitable (i) to submit to the Regulatory Authorities in the European
Union a MAA for the First Indication of the Product and (ii) for JANSSEN to obtain pricing and reimbursement for the Product in the EU and elsewhere where reasonably required by JANSSEN in the
Territory. 

* * * Confidential Treatment Requested * * *

12

 
	6.4
	LAB
will also provide to JANSSEN, at LAB's cost and expense and as reasonably required by JANSSEN, any samples, information, documentation and data LAB has in its possession (except
that which it may not disclose, if any, being subject to obligations of confidentiality to Third Parties) for the preparation and filing of any MAA or variation of an MAA required for the Product
other than the MAA identified in Section 6.3.

	6.5
	LAB
will promptly and at its cost and expense give reasonable assistance to JANSSEN in answering any questions from the Regulatory Authorities related to the Product.

	6.6
	JANSSEN
shall manage the GSD for the Product. The Parties shall enter into a separate Pharmacovigilance Agreement                * *
*                after signature of the Agreement. Such Pharmacovigilance Agreement shall be included as Schedule L and
shall set out roles and responsibilities of the Parties in the coordination with other territories where the Product is marketed. 

* * *  

All
Pharmacovigilance communications and transfer of information between the Parties shall be in the English language. 

7.     Commercial Efforts  

	7.1
	All
business decisions, including but not limited to the pricing, reimbursement, package design, sales, the choice of the JANSSEN Trademark and promotional activities and the decision
to launch or continue to market the Product in a particular country in the Territory, shall be within the sole discretion of JANSSEN and its Affiliates.

	7.2
	Notwithstanding
Section 7.1, JANSSEN and its Affiliates shall undertake commercially reasonable efforts to launch and market the Product in as many countries of the Territory
as possible, provided it makes reasonable business sense for JANSSEN, and to prioritize the Product accordingly, as JANSSEN and its Affiliates normally do for their own products having a similar
potential. Amongst other things, sales representatives promoting the Product shall be duly trained and shall have experience with analgesic products. In case JANSSEN or its Affiliates decide to use a
hired sales force, the same qualification and requirements shall apply.

	7.3
	During
the Term JANSSEN or its Affiliates or designees shall not distribute in the Territory another product in the Field. 

III.  MANUFACTURING AND SUPPLY  

8.     Manufacturing Responsibilities of LAB SRL  

	8.1
	Not
later than thirty (30) days after the dissolution of the JDT, the Parties shall form a Steering Committee which shall steer and coordinate further joint development,
manufacturing or clinical work on the Product according to the same decision making principles as applicable to the JDT. 

* * * Confidential Treatment Requested * * *

13

 
	8.2
	All
obligations, responsibilities and rights under this Section 8 belong on the side of LAB solely to LAB SRL. LAB SRL shall act as exclusive manufacturer and supplier of the
Product to JANSSEN or any designee of JANSSEN. For the avoidance of doubt, JANSSEN and its Affiliates are not allowed to manufacture the Product, except in the event of a Failure to Supply, according
to the terms and conditions set out in Section 11.3.

	8.3
	All
Products manufactured by LAB under this Agreement shall be processed and packaged strictly in accordance with the Product Specification  (Schedule B) and the Packaging Specification (Schedule J—as further specified
in Section 12). LAB will maintain the high standards and precautions customary among leading pharmaceutical product and device manufacturers and shall comply with (i) cGMP, as if the
Products were required to be CE-marked (as set out in Directive 93/42/EC), (ii) all applicable rules and regulations for opioids and other controlled substance including, but not
limited to the "Controlled Substances Act" as of October 27, 1970, codified at 21 U.S.C. § 801 as amended, (iii) all appropriate LAB Standard Operating Procedures as related
to the Manufacturing of the Product as amended from time to time, a list of which is attached as Schedule C to this Agreement.

	8.4
	LAB
shall perform all in-process and final quality control on the Product. Towards this end, parties shall enter into a Quality Agreement prior to the commencement of the
Phase III clinical trials. Such Quality Agreement shall constitute Schedule D to this Agreement.

	8.5
	LAB
shall send any documentation required by JANSSEN for approval of Product prior to shipment to JANSSEN. LAB shall only ship Product after receiving such authorization. JANSSEN
shall maintain final authority for release of the Product to the market in the Territory. Such Product release criteria, specific documentation and procedures will be outlined in the Quality Agreement
as set forth in Schedule D.

	8.6
	Furthermore,
LAB shall submit to JANSSEN a validation protocol for Product approval and shall validate the Manufacturing process according to the approved validation protocol on
                * * *                full
scale batches of the Product (the size of the batches being as set out in the Manufacturing Plan and the
Scale-up Plan as set forth in Schedules F and G). The Manufacturing Plan  (Schedule F) shall be added to
this Agreement not later than
                * * *                months after the Effective Date.

	8.7
	For
each batch of the Product, LAB shall take sample(s) according to the requirements of the Quality Agreement. Such sample(s) and records shall be retained in accordance with the
Quality Agreement.

	8.8
	Before
releasing each batch of the Product to JANSSEN or the party designated by JANSSEN, LAB shall undertake and will be responsible for the performance of final quality controls and
batch record review on the Product in accordance with the requirements of the Quality Agreement.

	8.9
	It
is expressly understood that this Section 8 is not intended to relieve LAB from its responsibility for following cGMP and meeting all appropriate and applicable regulatory,
safety and quality standards.

	8.10
	LAB
shall submit to JANSSEN (i) a complete batch record for each manufactured batch of Product and (ii) a sample of each manufactured batch of Product. JANSSEN shall
within                * * *                from receipt of the sample (i) perform, or have performed, the retesting by EU legislation,
(ii) review each batch record and, upon comparison of the batch records and retest results, advise LAB of the acceptance or rejection. 

Should
a batch of the Product or any of the Product fail to meet the standards of quality required and the approved release specifications under this Agreement, including  Schedule D and F, JANSSEN or its
Affiliates shall inform LAB in writing of the alleged shortcomings without undue delay but not later than within
                * * *                after
receiving said Products in the case on a non-latent defect, and
                * * *                from
confirmation by JANSSEN in case of a discovery by JANSSEN or                * *
*                days from first notice in case of a notice to JANSSEN by a Third Party in case of a latent defect. 

* * * Confidential Treatment Requested * * *

14

 

In
case of a latent defect JANSSEN will promptly notify LAB of the discovery or first notice of such defect to allow LAB to be involved in the investigation of the claimed latent defect. 

	8.11
	Without
prejudice to any other remedy which JANSSEN may have and upon completion of an appropriate investigation by the Parties of the final disposition of a batch or batches of the
Product which do(es) not meet the Product Specifications outlined in Schedule B, LAB shall replace at its own cost and expense, including
reimbursement of freight and disposition costs incurred by JANSSEN, the whole or part of the out of specification batch so rejected and shall destroy, upon JANSSEN's instructions and according to
LAB's standard procedure for destruction of the Product, the rejected batch of the Product which cannot be corrected. In case Parties disagree about the conformity of the Product, Section 19
shall apply. Parties will exercise all commercially reasonable efforts to complete the aforementioned investigation within                * *
*                from JANSSEN's notification set out in Section 8.10.

	8.12
	LAB
shall observe and comply with all applicable laws, ordinances, codes of practice and regulations of government agencies, including but not limited to, federal, state European and
local governing bodies having jurisdiction with respect to Manufacturing of the Product.

	8.13
	Without
prejudice to the generality of the foregoing, LAB and its officers confirm that they have read and understand the JOHNSON & JOHNSON Policy on the Employment of Young
Persons (the "Policy"), a copy of which forms Schedule E to this Agreement. In the manufacture and supply of the Product hereunder, LAB shall
employ young persons only as permitted by the Policy. LAB shall permit representatives of JANSSEN to enter LAB's premises at any reasonable time and on reasonable notice, and LAB shall ensure that
representatives of JANSSEN shall be permitted to enter the premises of any subcontractor involved in the manufacture or supply of the Product at any reasonable time and on reasonable notice, in order
to inspect relevant employment, health and safety records. LAB shall, if so requested, provide to JANSSEN a written certification, if available, of such compliance during the Term.

	8.14
	LAB
agrees to maintain a safe operating workplace for its employees through the use of appropriate and sufficient environmental controls and practices. 

* * *  

	8.15
	Should
LAB intend to assign one or more Manufacturing steps to one or more Subcontractors, LAB shall communicate in writing to JANSSEN the legal form and registered address of such
Subcontractor. Upon receipt of such communication for each proposed Subcontractor, JANSSEN shall have                * * *                to complete an
audit of such Subcontractor and notify LAB of any deficiencies. If JANSSEN notifies LAB of any deficiencies of the proposed Subcontractor during
such                * *
*                period, then the Parties shall attempt in good faith to resolve such deficiencies. If JANSSEN does not notify LAB of any such
deficiencies within such
                * * *                day
period, then such proposed Subcontractor shall be considered approved by JANSSEN for purposes of the Agreement;
and thereafter LAB shall be permitted to assign such Subcontractor as intended. In all cases, LAB shall ensure that such Subcontractors provide at least the same quality as expected from LAB under
this Agreement.

	8.16
	LAB
remains liable to JANSSEN for the full and proper performance of Manufacturing. The approved subcontracting shall not create any kind of contractual relationship between JANSSEN
and the Subcontractor unless otherwise provided by binding law. LAB shall ensure that each Subcontractor understands that (i) it shall not further subcontract and that (ii) its
performance shall be in strict compliance with all relevant Manufacturing provisions of this Agreement. 

* * * Confidential Treatment Requested * * *

15

 
	8.17
	LAB
shall act as exclusive manufacturer and supplier of Training Samples to JANSSEN or any designee of JANSSEN.

	8.18
	All
Training Samples shall be manufactured by LAB using the same standards and precautions customary among leading pharmaceutical product and device manufactures. Training Samples
shall comply with (i) cGMP, as if the Products were required to be CE-marked (as set out in Directive 93/42/EC) and (ii) all applicable LAB Standard Operating Procedures  (Schedule C).

	8.19
	From
time to time, JANSSEN shall order Training Samples from LAB in reasonable quantities to allow JANSSEN to adequately train health care professionals (including nurses and other
assisting personnel) and patients. LAB shall exercise commercially reasonable efforts to provide JANSSEN with such Training Samples without undue delay at cost plus 20%. 

9.     Warehousing  

	9.1
	LAB
shall provide adequate and safe storage (i) for all materials as shall be reasonably required at any given time for the Manufacturing operations to meet and support the
qualities of the Product and the agreed safety stocks and as agreed by forecast and (ii) for all Product pending delivery to JANSSEN or a party designated by JANSSEN in accordance with the
Product Specification and requirements according to the legislation on controlled substances.

	9.2
	LAB
shall take care to store the materials and Products in storage facilities adapted to the materials and the Product in compliance with applicable legal requirements and cGMP. The
location of LAB's warehouse in which the materials and the Product are stored, must at all times be known to and previously approved by JANSSEN.

	9.3
	LAB
shall keep any materials and Products owned by JANSSEN at all times secured and insured, at LAB's expense, for their replacement value against any loss or damage caused by any
event outside reasonable control of LAB, including, but not limited to, fire, theft, etc. 

10.   Manufacturing Equipment  

	10.1
	During
the Term, LAB shall operate and maintain the Manufacturing Equipment in accordance with good business practice. LAB warrants that its arrangements with Subcontractors shall
contain equal obligations for such Subcontractors.

	10.2
	JANSSEN
shall have the right to enter LAB's and its Subcontractors' facilities in order to (i) inspect the Manufacturing Equipment and (ii) inspect all records relating
to the repair, maintenance, servicing and replacement of the Manufacturing Equipment. JANSSEN shall be given access to such facilities, on reasonable notice, during normal business hours as long as
such facilities perform work subject to this Agreement.

	10.3
	During
the Term, LAB shall service, repair, maintain and replace the Manufacturing Equipment as may be necessary to keep the Manufacturing Equipment in good working order. 

11.   Inventory and Continuity of Supply  

	11.1
	LAB
will maintain inventory of the Product on a first-in, first-out basis. LAB shall maintain separate records showing opening and closing inventories of all
semi-finished and finished Product. Representatives of JANSSEN will have the right to inspect and to have access during reasonable business hours on reasonable notice, to such records
separately kept by LAB as are necessary to verify the accuracy of the reports made by LAB. Such representatives may take photocopies and other excerpts from such records. 

* * * Confidential Treatment Requested * * *

16

 
	11.2
	Not
later than                * * *                after JANSSEN has communicated to LAB its initial forecast as outlined in 13.2
below, LAB shall deliver to JANSSEN a continuity supply plan ("Continuity Supply Plan") so as to enable JANSSEN to maintain a commercial supply of Product at least sufficient to meet the requirements
of the market within its Territory and avoid stock-outs. The Continuity Supply Plan will provide contingency planning and implementation of appropriate measures to mitigate the impact of
events such as failures of Manufacturing Equipment and disasters to the supply of Product to JANSSEN and will include plans for maintaining adequate safety stocks of components and subassemblies,
spare parts to ensure the continued operability of moulds and equipment and other Manufacturing Equipment and disaster recovery plans. Without limiting the foregoing, the Continuity Supply Plan shall
provide that the minimum quantity of safety stock of the Products to be held by LAB, and its location, are to be agreed annually by the parties, no later than in January of each year for that calendar
year. For the first calendar year of production post launch of the Product, LAB shall hold                * * *                forecast supply of the
Product as safety stock at LAB approved warehouse facility. LAB, at its option, may decide to dedicate to these safety stocks and hold in inventory for JANSSEN more than the agreed minimum quantities,
but not more        * * *        the agreed minimums. LAB will notify JANSSEN in writing of any decisions on safety stock
quantities in
excess of the agreed minimums and make its decisions after consultation with JANSSEN. LAB shall use its commercially reasonable efforts to replenish any draw-down of safety stock within
                * * *                but
the replenishment lead time will depend on parameters such as quantities, production schedules, capacity, etc.,
which LAB will discuss with JANSSEN. In any event, LAB agrees to deliver all Product with no less than 75% of the remaining shelf-life existing at the time of shipment. JANSSEN will take
possession of the quantities they order via the forecast procedure without undue delay.

	11.3
	In
the event that LAB shall 

* * *  

(hereinafter
collectively referred to as a "Failure to Supply"), then JANSSEN, after due consultation with LAB about the causes of the problem, shall be licensed (with no obligation or liability to
LAB) upon            * * *                written
notice to LAB, to use, sell, make and have made Products pursuant to the licence
granted in Section 2. 

* * *  

Notwithstanding
anything to the contrary contained in this Agreement, in the event that JANSSEN shall make or have made the Product, pursuant to this Section 11, JANSSEN shall be permitted to
disclose to any Third Party such Confidential Information as is reasonably necessary in connection with such activities (subject to such Third Party agreeing in writing to be bound by the terms of
Section 31 hereof) and LAB shall reasonably assist in such disclosures. 

* * * Confidential Treatment Requested * * *

17

  

	11.4
	LAB
shall reasonably consult with JANSSEN in respect of any refurbishment or construction of facilities that LAB intends to undertake of facilities where the Products are or are
intended to be manufactured and shall ensure compliance with cGMP. For the avoidance of doubt, this requirement shall not release LAB from its obligations under Section 8 of this Agreement.

	11.5
	Upon
the start of Manufacturing, LAB shall disclose to JANSSEN a description of LAB's process for the manufacture of the Product in sufficiently clear and detailed terms that it can
be readily followed and carried out by a trained scientist or engineer to make the Product in the manner LAB considers most efficient. Furthermore, should LAB alter, modify or change its process for
manufacturing the Product in accordance with the terms of this Agreement, LAB shall amend the description to include such alteration, modification or change. The description pursuant to this Section
shall be used by JANSSEN or its designee only during a Failure to Supply.

	11.6
	During
any period when LAB is not supplying the Product to JANSSEN, for any Product sold by JANSSEN manufactured from another source, JANSSEN shall make payments to LAB OY as set
forth in Schedule I part c.

12.   Packaging and Labelling  

	12.1
	LAB
shall package the Product in accordance with the agreed Packaging Specification as defined in Schedule J, which may be
amended from time to time according to the procedures established in the Quality Agreement (Schedule D) for the modification of such
Specifications. The Packaging shall be in any event in a manner suitable for shipment and sufficient to enable the Products to withstand the effects of shipping, including handling during loading and
unloading.

	12.2
	JANSSEN
shall deliver to LAB for each country in the Territory to which the Product is to be delivered all labelling for the Product in a manner ready for reproduction. Within
                * * *                of the
Effective Date, the Parties shall agree on a standard procedure for the submission, approval and revision of
all labelling. An order shall not be accepted into the forecasting procedure unless labelling has been provided by JANSSEN. 

13.   Program of Manufacturing and Supply of the Product  

	13.1
	LAB
agrees to accept and Manufacture such quantities of the Product as are specified in written orders submitted from time to time to LAB by JANSSEN or a party designated by JANSSEN
according to the forecasting and ordering procedure. LAB shall undertake reasonable commercial efforts to fulfil, but is not be required to fulfil in orders in excess of more than
                * * *                of the
quantities (total) specified in the latest forecast period. 

JANSSEN
may submit purchase orders to LAB for quantities of the Product in excess of the forecast amounts pursuant this Section 13. LAB shall use commercially reasonable efforts to fulfil those
orders. If LAB expects to be unable to fulfil the portion of any such excess order within the time frame requested, then LAB shall notify JANSSEN
within                * *
*                working days after receipt of the purchase order. 

	13.2
	JANSSEN
shall notify to LAB within the first five days of each calendar month its monthly requirements for the Product for                * *
*                following the respective calendar month and an indicative estimate of its requirements for the
following                * *
*                period for capacity planning purposes. The first notification by JANSSEN shall take place no later than at the time of
filing of the first MAA.
Requirements and estimates shall be given per Product strength and on a country by country basis of the Territory. The first                * *
*                months of each forecast shall be considered as firm orders. Such finn orders will be confirmed via purchase orders, all of which
shall be issued at least
                * * *                days
in advance. Each purchase order will specify which amounts of each order will be packaged for which country (or
set of required labelling specifications). All orders will be for full batch quantities, and no mixed lots will be accepted. The current batch size is estimated at
                * * *                for
the                * * *                strength and
                * * *                for
the                * * *                strength. The Parties
will adjust the batch sizes during the development and scale-up period prior to initiation of the commercial forecast practice, and if so required, after manufacturing of the
                * * *                commercial batches of each strength. An order
containing                * *
*                percent more or less on quantity shall be considered filled in full. 

* * * Confidential Treatment Requested * * *

18

 
	13.3
	JANSSEN
shall be bound by the firm orders. Within                * * *                days from receipt of JANSSEN's order, LAB shall
confirm its acceptance thereof, in writing, indicating at the same time the approximate production week and the confirmed delivery date, such dates being within an absolute range of plus or minus
                * * *                from
the original specified date.

	13.4
	If
requested by JANSSEN, LAB shall render monthly and/or periodical inventory reports to JANSSEN, in such forms as JANSSEN shall specify, including the numbers of Products
manufactured for JANSSEN and still on hand. 

14.   Timely Production and Delivery  

Both
Parties understand that a timely production and delivery schedule of the Product is essential. In this respect LAB shall use all commercially reasonable efforts to prevent any delay in the agreed
upon production and delivery schedule, unless prevented by a Force Majeure Event and subject to Section 11.3 (Failure to Supply). 

15.   Price, Payment  

	15.1
	JANSSEN
will pay a Royalty on Net Sales to LAB and purchase Product from LAB at the Prices set out in Schedule I. All Prices
and risk of loss are                * * *                as defined in 1CC Incoterms 2000.

	15.2
	Payment
terms on all orders shall be                * * *                days net from receipt of invoice.

	15.3
	

* * *  

Within                * * *                after the end of each calendar quarter, JANSSEN shall deliver a report to LAB specifying, for such calendar
quarter in the Territory: the quantities of Product sold by JANSSEN and its distributors in each country in that calendar quarter and the Net sales (the "Sales Report"). 

Within                * * *                after the end of each calendar quarter, LAB shall deliver a report to JANSSEN specifying for such calendar
quarter and for the cumulative period from beginning of the calendar year till end of
such quarter, the quantities of Product produced and the actual Documented Manufacturing Cost for these quantities (the "Manufacturing Cost Report"). 

Within                * * *                after the end of each calendar quarter, JANSSEN shall deliver a report to LAB ("the Reconciliation Report")
that documents the actual price calculated using the actual Market Price per unit and the actual Documented Manufacturing Cost for such calendar quarter and for the cumulative period from beginning of
the calendar year till end of such quarter. This report will also document the difference between the actual Price per unit and the Forecast Price per unit and the total difference (differences in
unit price times total quantities sold). 

Within                * * *                after the end of the calendar year, JANSSEN shall deliver the full year Reconciliation Report to LAB. Based
on this, the Parties will settle the full year difference (full year difference in unit price times quantities sold). However, should a quarterly Reconciliation Report already report a cumulative
price difference bigger than                * * *                (up or down), than an intermediate settlement will be made within
                * * *                after issuance of the Reconciliation Report. The intermediate settlement will be equal to cumulative
difference actual vs. Forecast Price times actual cumulative units sold. 

* * * Confidential Treatment Requested * * *

19

 
	15.4
	

* * *  

	15.5
	JANSSEN
will keep, and will require that its Affiliates keep, accurate records of Net Sales. JANSSEN will allow, and will require that its Affiliates will allow, at LAB's sole
expense, an audit by an independent auditor selected by LAB (as to which JANSSEN has no reasonable objection). The auditor shall be permitted to audit the aforementioned records on a yearly basis upon
at least                * * *                advance notice during normal business hours, but not later
than                * *
*                following the rendering of any such records. Notwithstanding the above it is agreed that any audit will in a first instance be
discussed with JANSSEN. If the
auditor in good faith deems it necessary to go through detailed documents, the auditors shall have the right to audit the books of JANSSEN and its Affiliates. The auditors shall promptly make the
results of the audit available to LAB and JANSSEN. Any deviation determined by such audit shall be promptly paid or refunded as the case may be. If JANSSEN has underpaid payments by more than
                * * *                over
any reporting period, JANSSEN shall also reimburse LAB for the cost of such audit. The auditors will be bound
by confidentiality obligations and shall not reveal any information to LAB or its Affiliates obtained during such audit other than information strictly necessary to verify the basis and accuracy of
the payments under this Agreement.

	15.6
	LAB
will keep, and will require that its Affiliates keep, accurate records of Documented Manufacturing Cost. JANSSEN shall be entitled to appoint an independent auditor (to which LAB
has no reasonable objection) who shall be permitted to audit the aforementioned records on a yearly basis upon at least                * *
*                advance notice during normal business hours, but not later
than                * * *                following
the rendering of any such records. Notwithstanding the above it is agreed that any audit will in a first instance be discussed with LAB. If the auditor in good faith deems it necessary to go through
detailed documents, the auditors shall have the right to audit the books of LAB and its Affiliates. The auditors shall promptly make the results of the audit available to LAB and JANSSEN. Any
deviation determined by such audit shall be promptly paid or refunded as the case may be. If LAB has overstated the Documented Manufacturing Cost by more
than                *
* *                over any reporting period, LAB shall also reimburse JANSSEN for the cost of such audit. The auditors will be hound by
confidentiality obligations and shall
not reveal any information to JANSSEN or its Affiliates obtained during such audit other than information strictly necessary to verify the basis and accuracy of the payments under this Agreement. 

16.   Delivery  

LAB
will arrange for the Product to be delivered to the respective countries in the Territory in accordance with Sections 13 and 14. All charges for packing, hauling, storage, and bar coding are
included in the Price unless otherwise agreed to by the Parties. All shipments must be accompanied by a packing slip which describes the articles, states the purchase order number and shows the
shipment's destination. LAB agrees to promptly forward the original bill of lading or other shipping receipt for each shipment in accordance with JANSSEN's instructions. LAB further agrees to promptly
render, after delivery of goods or performance of services, correct and complete invoices to JANSSEN, and to accept payment by cheque or at JANSSEN's discretion, other cash equivalent (including
electronic transfer of funds). 

* * * Confidential Treatment Requested * * *

20

 

17.   Inspections  

	17.1
	JANSSEN
shall have the right, upon reasonable notice to LAB and during regular business hours, to inspect and audit while accompanied by LAB personnel the facilities being used by
LAB and any Affiliate or Subcontractor engaged by LAB for Manufacturing the Product, to assure compliance by LAB and, if applicable, its Subcontractors with cGMP, cGLP, cGCP and FDA, EMEA and other
applicable rules and regulations and with other provisions of this Agreement. LAB shall within                * * *                of receipt a written
notice from JANSSEN, remedy or cause the remedy of any deficiencies which may be noted in any such audit and specified in the written notice, or, in any such deficiencies can not reasonably be
remedied within such                * * *                period, present to JANSSEN a written plan to remedy such deficiencies as soon as possible; and
the failure by LAB to remedy or cause the remedy of any such deficiencies within such                * * *                or to present such a plan
within such                * * *                and then use its best efforts to remedy or cause the remedy of such deficiencies in accordance with such
written plan, as the case may be, shall be deemed a material breach of this Agreement. LAB acknowledges that the provisions of this Section 18 granting JANSSEN certain audit rights shall in no
way relieve LAB of any of its obligations under this Agreement, nor shall such provisions require JANSSEN to conduct any such audits.

	17.2
	The
Parties are aware that the EMEA "s Inspection Sector is responsible for the coordination of controlling systems under the Regulation 726/2004/EC, also together with the
different national Regulatory Authorities in Europe and elsewhere. Those inspections, which are covering for example the GCP, GLP, GMP and PhV of medical products, may arise after the MAA filed by
JANSSEN or LAB, as the case may be. Therefore, the Parties agree to fulfil all their obligations under such inspections and shall support the respective body when inspecting. Without prejudice to the
roles and responsibilities of the Parties as set out in the Pharmacovigilance Agreement (Schedule L), Parties shall make all commercially
reasonable efforts to collaborate as efficiently as possible. 

18.   Quality  

        LAB warrants that any Product sold to JANSSEN hereunder shall comply in all respects with the Product Specifications set out in  Schedule B (as amended from time to time) therefore and shall be free from defects in scale-up, manufacture, materials and
workmanship. 

19.   Independent Testing  

        If, after LAB's inspections of the Product, the Parties disagree as to the Products' conformance to the Product Specifications or whether the Product has such a
defect, either Party may deliver the Product to an independent Third-Party laboratory mutually and reasonably acceptable to both Parties, for analytical testing to confirm the Product's conformity or
non-conformity to the Product Specifications or the presence or absence of defects. All costs associated with such Third-Party testing shall be at JANSSEN's expense unless the tested
Product is deemed by such Third-Party to be defective or not in compliance with the Product Specifications, in which case all such costs, including
reimbursement of freight and disposition costs, shall be promptly paid by LAB. No inspection or testing of or payment for the Product by JANSSEN or any Third-Party agent of JANSSEN shall constitute
acceptance by JANSSEN thereof, nor shall any such inspection or testing be in lieu or substitution of any obligation of LAB for testing, inspection and quality control as provided in the Product
Specifications or under applicable local, state, federal laws, rules, regulations, standards, codes or statutes. 

* * * Confidential Treatment Requested * * *

21

 

20.   Recall  

	20.1
	In
the event any governmental agency having jurisdiction requests or orders, or if JANSSEN determines to undertake, any Recall, and the cause or basis of such Recall is attributable
to a breach by LAB of the warranty, LAB's liability shall be as set out in this Section.

	20.2
	JANSSEN
must use its reasonable endeavours to allow LAB a reasonable opportunity to inspect and, if required, remedy any Product before the Recall is taken and shall, to the extent
reasonably possible, reasonably consult with LAB prior to and during the Recall.

	20.3
	Subject
to Sections 25 and 26, LAB's maximum liability and JANSSEN's exclusive remedy, in respect of any Recall shall be limited 

* * *  

IV.    PATENTS—INFRINGEMENT  

21.   Patent Prosecution  

        LAB shall continue to be responsible for filing, prosecuting, maintaining and defending opposition proceedings against the Patents at its own cost. LAB will keep
JANSSEN informed of the status of each such Patent and application for such Patent. 

* * *  

22.   Infringement of Third Party's Patent Rights  

	22.1
	In
the event that the development, manufacture, use, promotion, marketing or sale of the Product is alleged to infringe or constitutes an infringement of intellectual property rights
of a Third Party (other than a violation by trade names or trademarks selected by JANSSEN or unfair competition claims) in a country of the Territory, or in the country of Manufacturing (regardless
whether in or outside the Territory), each Party shall, as soon as it becomes aware of the same, notify the other thereof in writing, giving in the same notice full details known to it of the claims
of such Third Party insofar as they relate to the Product and the extent of any alleged infringement. To the extent that the Product falls or is alleged to fall within the claims of a Third Party
patent, the Parties shall after receipt of such notice analyze the infringement claim, and to the extent necessary, attempt to agree on a course of action.

	22.2
	Should
the alleged infringement take place where the Product is actually marketed or a MAA has been filed, the Parties' aim shall be to permit JANSSEN to continue marketing the
Product in the Territory. 

* * *  

If
it is necessary in the judgment of JANSSEN to obtain a licence from such Third Party, then JANSSEN, with LAB's reasonable assistance, may negotiate for such a licence 

* * *  

* * * Confidential Treatment Requested * * *

22

 

* * *  

23.   Enforcement of Patents  

	23.1
	In
the event that in any country in the Territory in which JANSSEN, its Affiliates or licensees are marketing the Product, and JANSSEN, its Affiliates or licensees become aware of
the infringement of a Patent by a Third Party, JANSSEN or its Affiliates shall promptly notify LAB in writing to that effect, including with said written notice evidence establishing a prima facie
case of infringement by such Third Party.

	23.2
	LAB
has the right to take action to stop such infringement, including without limitation conducting patent infringement proceedings.                * *
*                JANSSEN will co-operate with LAB in any such suit and shall have the right to consult with LAB and be represented by its own
counsel at its own
expense. 

* * *  

	23.3
	

* * *  

	23.4
	

* * *  

* * * Confidential Treatment Requested * * *

23

 
	23.5
	

* * *  

 IV.    REPRESENTATIONS—WARRANTIES—INDEMNITIES—INSURANCE—LIMITATION OF LIABILITY  

24.   Representations and Warranties  

	24.1
	LAB
represents and warrants to JANSSEN as at the Effective Date that

	(a)
	LAB
International SRL is organized and in good standing under the laws of Barbados;

	(b)
	LAB
Pharma OY is organized and in good standing under the laws of Finland;

	(c)
	LAB
has the full power, authority and legal right to execute and deliver this Agreement, grant the rights granted to JANSSEN hereby and perform LAB's obligations and the other
agreements reference herein and therein;

	(d)
	The
execution, delivery and performance of this Agreement do not and will not violate (i) the by-laws of LAB or equivalent organisational document in LAB's
countries of organisation, or (ii) any provision of any agreement or other instrument or document to which LAB is a party or by which any of its assets or properties is bound or affected;

	(e)
	Other
than consents, authorisations, filings, notices and other acts that have been obtained or anticipated in this Agreement, no consent or authorisation of, filing with, notice to
or other act by or in request of, any governmental authority r any other person or entity, in the name of LAB, is required in connection with the execution, delivery, performance, validity or
enforceability of this Agreement.

	24.2
	LAB
represents and warrants that it has full authority to enter into this Agreement and that it has no knowledge at the date of this Agreement of (i) any actions, suits or
proceedings pending or threatened in writing against LAB, (ii) any circumstances which might give rise to such actions, suits or proceedings, or (iii) any Third Party rights that would
adversely affect performance by LAB of its obligations under this Agreement or JANSSEN's enjoyment of the rights granted to JANSSEN hereunder. More in particular, to the best of its knowledge, LAB
represents and warrants that it has sole and full ownership of all Patents, that they are and shall remain free from any encumbrances and that the manufacture, use, promotion, distribution and sale of
the Product in countries where the Product is covered by a Patent does not infringe the intellectual property rights of any Third Party. LAB does not warrant that a MA will be obtained.

	24.3
	LAB
represents and warrants that it is under no obligation, contractual or otherwise, to any other person, institution or other entity that would interfere with the rendering of
services called for in this Agreement.

	24.4
	LAB
represents and warrants that, to the best of LAB's knowledge, LAB has disclosed to JANSSEN any data and other information that could reasonably be considered material to the
safety or efficacy of the Product. 

* * * Confidential Treatment Requested * * *

24

 
	24.5
	JANSSEN
represents and warrants as at the Effective Date that:

	(a)
	JANSSEN
is organized and in good standing under the laws of Belgium;

	(b)
	JANSSEN
has the full power, authority and legal right to execute and deliver this Agreement and perform JANSSEN's obligations and the other agreements reference herein and therein. 

25.   Indemnity and Insurance  

	25.1
	LAB
shall indemnify JANSSEN and its Affiliates, their directors, officers, employees and representatives against and hold them harmless from all Third Party losses, claims, damages,
costs and expenses (including reasonable attorneys fees) to the extent arising out of, or resulting from (i) 

* * *  

	25.2
	JANSSEN
shall indemnify LAB and its Affiliates, their directors, officers, employees and representatives against and hold them harmless from all Third Party losses, claims, damages,
costs and expenses (including reasonable attorneys fees) to the extent arising out of, or resulting from (i) 

* * *  

	25.3
	LAB
agrees to procure and maintain in full force and effect during the term of this Agreement valid and collectible insurance policies, a copy of which is attached as  Schedule H. Upon JANSSEN's request,
 LAB shall provide to JANSSEN a copy of the certificate of insurance, evidencing such insurance coverage.

	25.4
	The
liability for a claim against either LAB or JANSSEN (each an "Indemnifier") in favour of JANSSEN or LAB (each an "Indemnitee"), respectively, pursuant to Section 25.1 or
25.2 (a "Claim"), as the case may be, shall be subject to the following conditions: 

* * *  

* * * Confidential Treatment Requested * * *

25

  

* * *  

26.   Limitation of Liability  

	26.1
	Nothing
in this Agreement will operate to exclude or limit the liability of either Party for death or personal injury arising out of its gross negligence or for its intent in any way
whatsoever.

	26.2
	Subject
to Section 26.1 and Section 22, LAB's maximum total liability (whether in contract, tort (including negligence) or otherwise) under or in connection with this
Agreement, will not exceed                * * *                for any one occurrence.

	26.3
	The
express terms of this Agreement are in lieu of all warranties, conditions, terms, representations, undertakings and obligations implied by statute, common law, custom, trade
usage, course of dealing or otherwise, all of which are excluded to the fullest extent permitted by law. 

V.     TERM AND TERMINATION  

27.   Term  

	27.1
	Unless
terminated earlier on any of the grounds in Section 28, the Term shall be as defined in Section 1.43.

	27.2
	The
Term may be extended at JANSSEN's option for subsequent periods of 2 years on the same terms and conditions on 12 months written notice before the expiry of the Term. 

28.   Termination  

	28.1
	In
the event of an Act of Insolvency or an Unauthorized Assignment by either Party, the other Party may terminate this Agreement or may avail itself of any remedies for termination
or continuation of the licences granted hereunder which it may have under applicable law, if such law allows the termination,

	28.2
	A
Party shall be deemed to commit an act of insolvency ("Act of Insolvency") if it applies for or consents to the appointment of a receiver, trustee or liquidator for all or a
substantial part of its assets; admits in writing its inability to pay its debts generally as they mature; makes a general assignment for the benefit of creditors; is adjudicated a bankrupt; submits a
petition or a request seeking an arrangement with creditors; takes advantage of any insolvency law; submits an answer admitting the material allegations of a petition in bankruptcy or insolvency
proceedings; has an order, judgment or decree entered against it by any court of competent jurisdiction approving a petition seeking its winding up, re-organization or appointing a
receiver, trustee or liquidator for it, or for a substantial part of any of its assets and such order, judgment or decree shall continue unstayed and in effect for any period of
                * * *                consecutive days; or files a voluntary petition in bankruptcy; or fails to remove an involuntary
petition in bankruptcy filed against it within                * * *                consecutive days of the filing thereof. 

This
Section 28.2 shall not apply to a voluntary winding up due to corporate restructuring if such restructuring does not harm or does not even improve the status of creditors. 

	28.3
	A
Party shall be deemed to have made an unauthorized assignment if it purports to assign or to grant a security interest in or otherwise encumber this Agreement without the prior
written consent of the other Party ("Unauthorized Assignment") other than a customary assignments of receivables to secure an ordinary bank loan. 

* * * Confidential Treatment Requested * * *

26

 
	28.4
	This
Agreement may be terminated by either Party by notice having immediate effect in the event of an Uncured Material Breach by the other Party. Failure of a Party (the "Defaulting
Party") to remedy a breach of any material duty or obligation required of the Defaulting Party under the terms of this Agreement within
                * * *                business days after receipt of written notice of such breach from the other Party shall be deemed an
uncured material breach ("Uncured Material Breach"). If LAB terminates by an uncured Material Breach by JANSSEN, all development results belong to LAB, including MA and MAA without further cost for
LAB. JANSSEN then shall reasonably support LAB to transfer such results, MA and MAA to LAB or a designee of LAB. 

The
Parties agree that in the event that LAB commits an Uncured Material Breach, then in any arbitration proceedings brought by JANSSEN pursuant to Section 40.2 the arbitrators shall be
empowered, at the request of JANSSEN and the discretion of the arbitrators, to reduce the Price otherwise payable by JANSSEN to redeem the actual damages incurred by JANSSEN as a result of the Uncured
Material Breach by LAB. 

	28.5
	Except
during the                * * *                after the Effective Date, JANSSEN reserves the right to terminate this Agreement
at any time upon                * * *                written notice. In such event JANSSEN shall be obligated to pay LAB only for (a) 

* * *  

Notwithstanding
the above, JANSSEN shall have the right to terminate this Agreement during the Development Period upon                * *
*                prior written notice in case any event occurs (including, but not limited to major safety issues in the clinical development of
the Product) that would by
generally accepted standards prevent JANSSEN or LAB to submit a MAA. 

	28.6
	All
rights to terminate shall be executed for the whole Territory or for single or more countries in the Territory, which than shall be reduced accordingly. Any termination of this
Agreement shall not affect existing payment obligations and such payments deemed to be due at the same time when the termination may come due.

	28.7
	Should
JANSSEN decide not to launch the Product not even in one country of the                * * *                after the First
Marketing Authorization (including pricing) of the Product, LAB may terminate the Agreement. Should JANSSEN decide not to launch the Product                * *
*                the Territory outside                * * *                of the Product, LAB may terminate the Agreement for
such respective country. In such cases of Termination Section 28.5 sentences three and four (3 and 4) above shall apply. 

VI.   MISCELLANEOUS  

29.   Employees  

        Nothing contained in this Agreement is intended or is to be construed to constitute LAB and JANSSEN as partners of joint ventures or either Party as an employee
of the other. Neither Party hereto shall have any express or implied rights or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party
to any contract, agreement or undertaking with any Third Party. 

* * * Confidential Treatment Requested * * *

27

 

30.   Permits  

        LAB shall maintain all government permits and licenses, including but not limited to, health, safety and environmental permits, necessary for the conduct of the
activities and procedures that LAB undertakes pursuant to this Agreement. 

31.   Confidential Information  

        During the term of this Agreement and for a period of                * *
*                thereafter, JANSSEN and
LAB agree to hold all Confidential Information in confidence for the disclosing Party and not to disclose the Confidential Information of the other party to any Third Party other than an Affiliate,
agent or consultant, except those who need to know such Confidential Information for purposes of carrying out the terms of this Agreement and who, including Affiliates, are bound by an equivalent
obligation of confidentiality and non-use, and not to use such Confidential Information for any purpose other than for the purposes of this Agreement. 

32.   Force Majeure  

        Except as expressly stated otherwise in this Agreement, each of the Parties hereto shall be excused from the performance of its obligations hereunder in the event
such performance is prevented by a Force Majeure Event and such excuse shall continue as long as the condition constituting such Force Majeure Event continues, plus
                * * *                days
after the termination of such condition. 

33.   Notices  

        All notices, demands and communications provided for in this Agreement shall be in writing and shall be deemed effective by a Party upon hand delivery or when
mailed, postage prepaid, by registered or certified mail, or by telecopy when received to the other Party or its copy designee at the respective addresses listed below, unless and until such address
is changed by giving written notice thereof in like manner. 

To
LAB INTERNATIONAL SRL

Windmark, Harts Gap, Christ Church, Barbados, West Indies

Attention: Managing Director Dr. Halvor Jaeger

Fax No: ++1 246 435 3262 

To
LAB PHARMA OY

Biolinja 12, 20750 Turku, Finland

Attention: Stephen Lermer, President

Fax No: ++358 2 33324444 

To
JANSSEN:

JANSSEN PHARMACEUTICA NV

Turnhoutseweg 30, B-2340 Beerse

Attention: Managing Director

Fax No:+ +32 14 60 31 79

cc. J&J Law Department Europe

Fax No: ++32 2 749 25 59 

* * * Confidential Treatment Requested * * *

28

 

34.   Publicity  

        Neither Party shall originate any publicity, news release or public announcements, written or oral, whether to the public or press, stockholders or otherwise,
relating to this Agreement, including its existence, without the prior written consent of the other Party, which shall not be unreasonably withheld. If a Party believes that it has legal requirement
to make public the existence of or any details of or any events related in any way to this Agreement, it shall provide a copy of any such announcement to the other Party for review and approval at
least                * * *                prior to making said announcement or, if the legal requirement does not reasonably allow such
                * * *                notice,
 without undue delay Both Parties shall reasonably co-operate with each other so as to ensure
that any such reports can be reviewed and issued in accordance with the above timelines. 

35.   Expenses  

        Each Party shall pay all of its own fees and expenses (including all legal, accounting and other advisory fees) incurred in connection with the negotiation and
execution of this Agreement and the arrangements contemplated hereby 

36.   Assignment  

	36.1
	JANSSEN
may assign or delegate all or any of its rights and obligations under this Agreement to an Affiliate without the prior consent of LAB. In the event JANSSEN assigns all or any
parts of its rights and obligations hereunder to an Affiliate, LAB shall at the request of JANSSEN enter into with such Affiliate, such supplemental agreements not inconsistent herewith as may be
necessary or advisable to permit such Affiliate to avail itself of or perform any right or obligation of JANSSEN hereunder. Any such assignment or delegation shall not alleviate JANSSEN of its
obligation hereunder.

	36.2
	LAB
may assign or delegate to an Affiliate of LAB, all or any of its rights, obligations and intellectual property under this Agreement, but in no event shall such assignment or
delegation (i) be deemed to relieve LAB of its liabilities or obligations to JANSSEN under this Agreement or (ii) adversely affect the financial, fiscal and commercial position of
JANSSEN. LAB expressly acknowledges and agrees that LAB shall remain fully and unconditionally obligated and responsible for the full and complete performance of all of LAB's obligations under the
terms and conditions of this Agreement. JANSSEN shall at the request of LAB enter into such supplemental agreements with any such Affiliate of LAB not inconsistent herewith as may be necessary or
advisable to permit such Affiliate to avail itself of or perform any right or obligation of LAB hereunder. 

37.   Severability  

        The provisions of this Agreement shall be deemed severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability
of the other provisions hereof. If any provision of this Agreement, or the application thereof to any person or entity or any circumstance, is invalid or unenforceable, (i) a suitable and
equitable provision shall be substituted therefore in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid and unenforceable provision and (ii) the
remainder of this Agreement and the application of such provision to other persons, entities or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or
unenforceability of such provision, or the application thereof, in any other jurisdiction. 

* * * Confidential Treatment Requested * * *

29

 

38.   Entire Agreement—Sole benefit of the Parties—Amendments  

	38.1
	This
Agreement and its appendices embody the entire understanding and agreement among the Parties and supersedes all previous negotiations, representations, writings and agreements,
written or oral, with respect to the subject matter of this Agreement.

	38.2
	This
Agreement is intended to be solely for the benefit of the Parties hereto and no term of this Agreement shall be enforceable by a person who is not a party to this Agreement.

	38.3
	No
modification, amendment, variation, extension or waiver of this Agreement or any provision hereof shall be binding or effective unless in writing and signed by a duly authorized
representative of each of the Parties. 

39.   Conflicts  

        To the extent of any conflict or inconsistency between this Agreement and any purchase order, purchase order release, confirmation, acceptance or any similar
document, the terms of this Agreement shall govern. 

40.   Dispute, Governing Law & Jurisdiction  

	40.1
	This
Agreement shall be governed by and construed in accordance with the laws of                * * *                

	40.2
	The
Parties will attempt in good faith to resolve any dispute arising out of or relating to this Agreement promptly by negotiation between executives of the Parties.

	(a)
	Any
controversy or claim arising out of or relating to this Agreement, including any such controversy or claim involving Affiliates of any Party (a "Dispute"), shall first be
submitted to mediation according to                * * *                Such mediation shall be attended on behalf of each party for at
least one session by a senior business person with authority to resolve the Dispute. Any period of limitations that would otherwise expire between the initiation of mediation and its conclusion shall
be extended until                * * *                after the conclusion of the mediation.

	(b)
	Any
Dispute that cannot be resolved by mediation within                * * *                of notice by one party to the other of the
existence of a Dispute (unless the parties agree to extend that period) shall be resolved by arbitration in accordance with the                * *
*                The arbitration shall be conducted in the English language
in                * * *                by
three
arbitrators, one named by each party and the third appointed in accordance with                * * *                The arbitrators, by accepting
appointment, undertake to exert their best efforts to conduct the process so as to issue an award within                * * *                of the
appointment of the last arbitrator, but failure to meet that timetable shall not affect the validity of the award. The arbitrators shall decide the Dispute in accordance with the law governing this
Agreement. The award of the arbitrators may be entered in any court of competent jurisdiction. 

* * * Confidential Treatment Requested * * *

30

 

41.   Counterparts  

        This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same
instrument. 

        IN
WITNESS WHEREOF, the Parties have caused this Agreement to be executed and delivered on the date first written above by their duly authorized representatives. 

	

LAB INTERNATIONAL SRL
	By:	 	/s/ DR. HALVOR JAEGER
	 	June 17, 2002
	Name: Dr. Halvor Jaeger
	Title: Chief Executive Officer
	

LAB PHARMA OY
	By:	 	/s/ STEPHEN LERMER
	 	June 16, 2007
	Name: Stephen Lermer
	Title: President
	

JANSSEN PHARMACEUTICA NV
	By:	 	/s/ RENE HEK
	 	June 20, 2007
	Name: Rene Hek
	Title: Vice President Finance and CFO
	

By:	
 	

/s/ ROGER COX
	
 	

June 20, 2007
	Name: Roger Cox
	Title: Executive Director Licensing

* * * Confidential Treatment Requested * * *

31

QuickLinks

Exhibit 10.5

EXCLUSIVE LICENCE, DEVELOPMENT AND SUPPLY AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00130-of-00352.parquet"}]]